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On the infrequent occasions when I have been called upon in a
formal place to play the bongo drums, the introducer never seems to
find it necessary to mention that I also do theoretical physics.
— Richard Feynman
Messenger Lectures at Cornell University (1964-5)
Dedicated to my family

S U M M A RY
The target of rapamycin (TOR) is a conserved protein kinase and a
central controller of growth. TOR can be part of two structurally and
functionally distinct complexes, termed TOR complex 1 and TOR
complex 2. Mammalian TOR complex 2 (mTORC2) is composed of
mTOR, Rictor, Sin1 and mLST8. Both mTORC1 and mTORC2 are ac-
tivated by growth factors. The mechanism via which growth factors
regulate mTORC2 has been elusive until recently. mTORC2 binds ri-
bosomes in a growth factor stimulated manner and this association is
required for mTORC2 activity.
mTOR complex 2 functions include control of spatial cell growth
and metabolism and thus, mTORC2 deregulation has been linked
to various disorders including cancer and diabetes. mTORC2 phos-
phorylates and thereby activates the AGC kinase family member Akt
(PKB). Akt has many different targets and functions, not all of which
depend on mTORC2 mediated Akt phosphorylation.
In order to gain a better understanding of mTORC2 function, we
asked where mTORC2 signaling is localized. A number of studies
localized mTORC2, functionally or physically, either to the endoplas-
mic reticulum (ER) or to mitochondria. We investigated whether these
seemingly unrelated observations concerning mTORC2 localization,
might be the consequence of mTORC2 signaling at MAM. MAM
or mitochondria-associated ER membrane is a quasi-synaptic subdo-
main between the ER and mitochondria. MAM plays a crucial role in
the regulation of mitochondrial metabolism and cell survival by gat-
ing both the calcium flux and phospholipid trafficking between the
ER and mitochondria.
First, we analyzed mTORC2 subcellular localization. mTORC2 is
localized to the ER adjacent to mitochondria and mTORC2 can be
biochemically isolated from MAM structures. mTOR complex 2 inter-
acts with the IP3R-Grp75-VDAC1 complex, a tether that connects ER
and mitochondria at MAM. Insulin stimulates mTORC2 localization
to MAM and mTORC2 interaction with the IP3R-Grp75-VDAC1 com-
plex. MAM localization of mTORC2 depends on mTORC2-ribosome
interaction.
Next we investigated the function of mTORC2 at MAM. Rictor
(mTORC2) knockout causes a decrease in MAM formation. Growth
factors stimulate MAM formation via mTORC2 and the Akt substrate
PACS2, a MAM resident protein. As expected for MAM deficient
cells, mTORC2 disruption changes the calcium flux from the ER to
mitochondria at MAM. Furthermore, we observe a reduction of Akt
mediated phosphorylation of the MAM calcium channel IP3R upon
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Rictor knockout. Thus, mTORC2 signaling at MAM controls MAM-
mediated calcium release via the Akt targets PACS2 and IP3R.
Since MAM disruption and calcium signaling both affect mitochon-
drial metabolism, we proceeded by analyzing the mitochondrial phys-
iology of mTORC2 deficient cells. Rictor knockout cells exhibit a dis-
ruption of VDAC1-HK2 binding, caused by a lack of Akt mediated
phosphorylation of HK2 at MAM. This, together with the defect in
MAM, induces an increase in basal respiration, mitochondrial inner
membrane potential, and ATP production in the mTORC2 deficient
cells, culminating in apoptosis. Thus, mTORC2 at MAM appears to
control several aspects of mitochondrial physiology.
These findings emphasize the role of MAM as a signaling hub that
controls cell physiology. By identifying the integral role of mTORC2
at the core of this platform, our results provide new insights on
the mechanisms that regulate growth and metabolism. These obser-
vations may offer new therapeutic strategies against mTORC2 and
MAM driven diseases such as diabetes, Alzheimer’s and cancer.
The results section of this thesis consists of the manuscript submit-
ted to Molecular Cell. A number of complementing observations are
presented in Section 2.2. The study characterizing the liver-specific
knockout of Rictor, has important implications for my thesis and is
presented as an appendix in Section 3.1.
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Novel findings:
• mTORC2 localizes to MAM
• mTORC2 at MAM interacts with the IP3R-Grp75-VDAC1 com-
plex and ribosomes
• mTORC2 at MAM phosphorylates Akt
• mTORC2 controls growth factor stimulated MAM formation via
the Akt substrate PACS2
• mTORC2 controls MAM calcium release by regulating MAM
integrity and the Akt substrate IP3R
• mTORC2 at MAM controls mitochondrial function via PACS2,
IP3R and HK2
• MAM is an mTORC2-Akt signaling hub
Graphical abstract
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And once the storm is over, you won’t remember how you made it through,
how you managed to survive. You won’t even be sure, whether the storm is
really over. But one thing is certain. When you come out of the storm, you
won’t be the same person who walked in. That’s what this storm’s all about.
—Haruki Murakami, Kafka on the shore
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I N T R O D U C T I O N
1.1 tor signaling
1.1.1 Discovery and history of TOR
1.1.1.1 Rapamycin
The history of TOR research begins in 1965 on Rapa Nui, better
known as Easter Island. A research team found that the common bac-
terium Streptomyces hygroscopicus isolated from one of their soil sam-
ples, secreted a macrolide that inhibits growth of the fungus Candida
albicans, and, accordingly, they named this novel antibiotic rapamycin
(Vézina et al., 1975). Importantly, rapamycin was subsequently found
to also have immunosuppressive and anti-proliferative properties in
mammalian cells. Over 20 years later, rapamycin was approved for
use in post-transplantational immunosuppression (Camardo, 2003).
1.1.1.2 Discovery of TOR
The growth inhibitory effect of rapamycin spiked an interest in iden-
tifying its target protein. Saccharomyces cerevisiae is an ideal model
system to perform genetic screens to identify rapamycin resistant mu-
tants. In 1991, a study identified three genes in yeast that upon loss
confer rapamycin resistance (Heitman et al., 1991). One of these genes
was the immunophillin FKBP12 (FK506 binding protein 12, a prolyl
isomerase). FKBP12 was at the time already known to mediate the
effect of FK506 (another immunosuppressant structurally related to
rapamycin) toward calcineurin. FKBP12 is highly conserved among
eukaryotes, with the exception of A. thaliana and C. elegans, both of
which lack a rapamycin binding FKBP12 homolog and thus are ra-
pamycin resistant.
Another class of mutations was found in two related genes termed
TOR1 (target of rapamycin 1) and TOR2 (Heitman et al., 1991). This
important discovery marks the foundation of TOR research and sub-
sequent investigations revealed that TOR is part of two protein com-
plexes, only one of which is targeted allosterically by the rapamycin-
FKBP12 complex. Both the use of the specific inhibitor rapamycin and
the combination of biochemistry and genetics in yeast greatly facili-
tated the subsequent research on the two TOR complexes (Loewith
et al., 2002).
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1.1.1.3 Conservation of TOR
TOR is structurally and functionally conserved throughout eukary-
otic evolution, as the effect of rapamycin on both yeast and mam-
malian cells had already suggested. Mammalian TOR (mTOR) was
discovered in 1994 and found to control growth in a similar manner
as in yeast (Brown et al., 1994; Sabatini et al., 1994; Chiu et al., 1994;
Sabers et al., 1995). In yeast, nutrient (i.e. nitrogen and amino acids)
availability is relayed to TOR (Barbet et al., 1996; Hara et al., 1998;
X Wang, 1998). Multicellular organisms, presenting a further dimen-
sion of growth control, also feed growth factor signaling to TOR, in
order to control and synchronize whole body growth and metabolism.
The following parts will mostly address the single mammalian TOR
gene, called mTOR.
A selection of recent, TOR-related reviews
Laplante and Sabatini (2012) mTOR in growth and disease
Appenzeller-Herzog and Hall (2012) mTOR and the ER
Durán and Hall (2012) TOR and GTPases
Oh and Jacinto (2011) mTORC2 review
Efeyan and Sabatini (2010) mTOR and cancer
Pearce et al. (2010) AGC kinases
Laplante and Sabatini (2009b) mTOR and lipid biosynthesis
Cybulski and Hall (2009) mTORC2 review
Soulard et al. (2009) TOR signaling in invertebrates
Blagosklonny and Hall (2009) Growth and aging
1.1.2 Organization of domains in TOR
TOR is the founding member of a kinase family called PIKK (phos-
phoinositide kinase-related kinase) family that comprises ATM, ATR,
DNA-PK, SMG1, TRRAP and TOR. All members of this atypical ki-
nase family are protein kinases, even though they are structurally
related to phosphoinositide 3-kinases (PI3Ks) and PI4Ks which are
lipid kinases (Benjamin et al., 2011). The PIKKs share similar domain
organization with a ± 600 residue helical domain (FAT) and a shorter
(± 70 residues), similar domain at the C-terminus (FATC). Only TOR
contains a FRB domain (± 100 residues) between the helical FAT
and the catalytic kinase domain (± 370 residues). FRB, the FKBP12-
rapamycin binding domain, is presumably masked in TORC2 by one
of the specific subunits (Hall, 2008). A large part of the N-terminal
part of TOR is formed by roughly 20 HEAT (huntingtin, elongation
factor 3, PP2A and TOR) repeats, a domain that most likely forms an
extended superhelical structure (Groves, 1999) and that plays a role
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in protein-protein interaction with Raptor, one of the mTOR complex
1 (mTORC1) subunits (Kim et al., 2002). In between the catalytic do-
main and the FATC domain is the FIT domain (Found In TOR) that in
mTOR encompasses several phosphorylation sites (Sturgill and Hall,
2009).
The TOR complexes most likely exist as dimers. mTORC1 dimeriza-
tion is nutrient- but not growth factor-responsive (Zhang et al., 2006b;
Takahara et al., 2006) although the role of this organization is not yet
known (Wullschleger et al., 2005; Yip et al., 2010). One hypothesis
is that dimerization of the mTOR complex facilitates intramolecular
phosphorylation. Currently, only a low resolution 3D structure model
of mTORC1 is published. This model comes from cryo-electron micro-
scopic images and shows mTORC1 as a dimer (Yip et al., 2010).
Interestingly, there is a splice variant of mTOR, called mTORβ
(Panasyuk et al., 2009). It is a short isoform and in comparison to full
length mTOR, mTORβ induces higher S6K and Akt phosphorylation
when overexpressed. mTORβ is believed to be tumorigenic.
1.1.3 Components of the mTOR complexes
1.1.3.1 mTORC1
mTOR complex 1 is composed of mTOR, Raptor and mLST8. Rap-
tor (Kog1 in yeast) plays an essential role in mTORC1 by stabilizing
the complex (Kim and Sabatini, 2004) and by recruiting substrates to
mTOR via interaction of its RNC (Raptor N-terminal conserved) do-
main with the TOS motif found in some TOR substrates (Nojima et al.,
2003; Schalm et al., 2003; Adami et al., 2007). mLST8 (mammalian
lethal with sec thirteen 8) is a small protein composed of 7 WD40 re-
peats that is found both in mTORC1 and mTORC2. mLST8 enhances
mTOR kinase activity of mTORC1 (Kim et al., 2003; Wullschleger
et al., 2006). However, mLST8 presence is required for mTORC2 but
not mTORC1 activity (Guertin et al., 2006; Wang et al., 2012).
PRAS40 (AKT1S1) can associate with mTORC1 and acts as a neg-
ative regulator towards mTORC1 activity (Sancak et al., 2007; Van-
der Haar et al., 2007). Deptor can interact with both mTOR complexes
and can regulate mTOR activity both positively and negatively (Pe-
terson et al., 2009). Deptor contains two DEP domains (disheveled,
egl-10, pleckstrin) and a PDZ (postsynaptic density 95, discs large,
zonula occludens-1) domain. Deptor expression and translation are
regulated by mTORC1 and mTORC2. Both PRAS40 and Deptor are
not considered to be integral mTOR complex components.
1.1.3.2 mTORC2
mTOR complex 2 is composed of mTOR, Rictor, Sin1 and mLST8.
Rictor is homologous to Avo3 in yeast (25% identity) (Jacinto et al.,
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2004). No obvious domains can be identified in Rictor, however the C-
terminal part is highly conserved in vertebrates. Sin1 is homologous
to Avo1 in yeast (Frias et al., 2006; Jacinto et al., 2006). Sin1 under-
goes alternative splicing and gives rise to 5 different isoforms, termed
Sin1.1-Sin1.5. Sin1.1, Sin1.2 and Sin1.5 can be part of mTORC2, while
Sin1.3 is not expressed in HeLa cells and was not further studied
(Cheng et al., 2005; Frias et al., 2006). Sin1.1 and Sin1.2 both have a
pleckstrin homology (PH) domain that presumably associates them
with membranes. Other domains in Sin1 are the conserved region
in the middle (CRIM) and the ras-binding domain (RBD). Among
the mTORC2 binding Sin1 isoforms, RBD is only found in Sin1.1. The
RBD domain was found to bind and activate Ras when overexpressed
(Schroder et al., 2007). Sin1.5 might be part of an insulin insensi-
tive mTORC2 (Frias et al., 2006). The different Sin1 isoforms suggest
the existence of at least 3 different mTORC2s. It is unknown which
role these different complexes play in mTORC2 signaling. Sin1 fur-
thermore has mTORC2 independent functions in the stress response
(Cheng et al., 2005; Schroder et al., 2007; Makino et al., 2006; Schroder
et al., 2005; Ghosh et al., 2008). Rictor and Sin1 stabilize each other, as
deletion of one can affect the levels of the other (Jacinto et al., 2006;
Guertin et al., 2006; Yang et al., 2006). mLST8 deletion inhibits associ-
ation of Rictor with mTOR but not association of Raptor with mTOR
or that of Rictor with Sin1 (Guertin et al., 2006; García-Martínez and
Alessi, 2008).
Another class of mTORC2 interacting proteins is PRR5/PRR5L (Pro-
tor 1/2) that bear minimal sequence homologies to the yeast TORC2
component Bit61 (Pearce et al., 2007; Woo et al., 2007; Thedieck et al.,
2007). PRR5/PRR5L are the only non essential mTORC2 components.
PRR5 is in a complex with Rictor even when mTORC2 is disrupted.
Rictor regulates PRR5 expression and PRR5 is overexpressed in cer-
tain cancers (Johnstone et al., 2005; Oh and Jacinto, 2011).
Other less well studied factors interact with mTORC2 but should
not be considered as components of the complex. Hsp70 binds Rictor
and depletion of Hsp70 affects mTORC2 activity (Martin et al., 2008).
Tel2 and Tti play a role in mTOR complex formation and stability
(Takai et al., 2007; Kaizuka et al., 2010).
1.1.4 Regulation of the mTOR complexes
1.1.4.1 Upstream regulation of mTORC1
Because of the availability of specific mTORC1 inhibitors, upstream
signaling of mTORC1 is generally better understood than that of
mTORC2. mTORC1 can be posttranslationaly modified. mTOR, pri-
marily in mTORC1 but also in mTORC2 is phosphorylated at S2448.
However it is not clear whether this phosphorylation affects mTORC1
activity.
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Deptor, as mentioned above, associates with both mTOR complexes.
Its function is not entirely clear, but it might negatively regulate their
activity under some conditions, while acting positively in others (Pe-
terson et al., 2009). Interestingly, Deptor expression and translation
are negatively regulated by the two mTOR complexes. It should be
noted however that the logic and mechanism of this regulatory loop
are not well understood at this moment.
HEAT HEAT FAT FR
B Kinase
FA
TC
Raptor mLST8
mTORC1
growth factors
low energy
stress
hypoxia amino acids
PI3K
Akt
TSC1/2
Rheb
AMPK
 REDD1
MAP4K3
RagGTPases
Vps34
Deptor
Rapamycin
FKBP12 ATP analogs
Figure 1: mTORC1 regulation
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nutrients Amino acids are necessary for mTORC1 activity (Hara
et al., 1998; X Wang, 1998). The exact sensing mechanism is only par-
tially understood and includes MAP4K3 (Findlay et al., 2007; Yan
et al., 2010), VPS34 (Gulati et al., 2008; Nobukuni et al., 2005) and
the Rag GTPases (Sancak et al., 2008; Kim et al., 2008). Upon amino
acid availability, Raptor interacts with the RagA/RagB RagC/RagD
heterodimer, associating mTORC1 with the lysosomal surface. At the
lysosome, GTP-bound Rheb (stimulated by growth factors), activates
TOR. Rag activity depends on GTP/GDP loading state and one of
the mechanisms by which leucine and glutamine activate Rags, is
through glutaminolysis (Durán et al., 2012).
growth factors Insulin and other growth factors activate PI3K.
PI3K phosphorylates PIP2 to form PIP3 in the plasma membrane. Akt,
via its PH domain, can bind to PIP3. Akt is then activated by PDK1-
mediated phosphorylation at T308. Akt in turn phosphorylates TSC2,
thereby inhibiting the GAP activity of the TSC1/TSC2 complex and
favoring Rheb-GTP loading (Inoki et al., 2002; Manning et al., 2002;
Potter et al., 2002; Garami et al., 2003; Inoki et al., 2003; Tee et al.,
2003). A GEF for Rheb is currently unknown. As mentioned earlier,
Rheb-GTP at the lysosome then activates mTORC1 if amino acids are
present. Accordingly, Rheb is responsible for both amino acid and
growth factor mediated activation of mTORC1. Thus, overexpression
of Rheb rescues mTORC1 activity even under absence of growth fac-
tors or amino acids.
Akt also regulates mTORC1 by phosphorylating PRAS40, thereby
sequestering it away from mTORC1 and alleviating the inhibitory role
of PRAS40 toward mTORC1 (Kovacina et al., 2003). Further signaling
inputs from growth factors come from Erk and GSK3β phosphoryla-
tion of TSC2 (Ma et al., 2005; Castilho et al., 2009; Inoki et al., 2006).
energy mTOR complex 1 senses the cellular energy status through
AMPK (Hardie, 2007). If the AMP:ATP ratio rises, AMPK phosphory-
lates TSC2, and this presumably stimulates TSC GAP activity (Cor-
radetti et al., 2004). AMPK also phosphorylates and thereby inhibits
Raptor (Gwinn et al., 2008). This arm of mTORC1 signaling guaran-
tees mTORC1 inhibition when energy levels are low.
stress Some forms of stress such as hypoxia also act through the
above mentioned AMPK-mTORC1 route. Hypoxia furthermore re-
duces mTORC1 activity through REDD1 (Zoncu et al., 2010). DNA
damage inhibits mTORC1 via p53-AMPK (Feng et al., 2007; Jones
et al., 2005)
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1.1.4.2 Upstream regulation of mTORC2
mTORC2 is stimulated by growth factors. Growth factors, via PI3K,
induce mTORC2-ribosome association (Oh et al., 2010; Zinzalla et al.,
2011). Active mTORC2 binds to the large ribosomal subunit, inde-
pendently of translation. Ribosome perturbation leads to a loss of
TORC2 activity in yeast and mammals, even though growth factor
signaling has been grafted onto TORC2 signaling at an evolutionary
later step. The exact mechanism of how ribosome binding might in-
fluence mTORC2 activity is unknown. One hypothesis is that the ribo-
some anchors mTORC2 inside the cell at a localization that activates
mTORC2.
mTORC2 is generally thought not to be regulated by nutrients,
however there are conflicting observations regarding mTORC2 activa-
tion by amino acids (Tato et al., 2011; Nobukuni et al., 2005; Hernández-
Negrete et al., 2007).
Several posttranslational modifications affect mTORC2 activity di-
rectly. Rictor can be acetylated, a modification that stabilizes mTORC2
(Glidden et al., 2012). mTOR in mTORC2 can be autophosphorylated
at S2481, and this phosphorylation might be a marker for mTORC2 ra-
pamycin sensitivity (Copp et al., 2009). S2481 is also sensitive to PI3K
inhibition (Peterson et al., 2000). Nevertheless, the functional conse-
quence of this phosphorylation is not yet understood (Copp et al.,
2009; Soliman et al., 2010). Rictor and Sin1 are phosphorylated on
multiple sites (Akcakanat et al., 2007; Dibble et al., 2009). For exam-
ple, Rictor is phosphorylated at T1135 by S6K1. However, conflicting
observations were reported as to whether this phosphorylation is in-
hibitory (Julien et al., 2010; Treins et al., 2010; Boulbes et al., 2010). Fur-
thermore, Rictor is phosphorylated at S1235 by GSK3β in response
to ER stress (Chen et al., 2011). There might be alternative ways by
which ER stress inhibits mTORC2 signaling (Appenzeller-Herzog and
Hall, 2012). Sin1 phosphorylation enhances its binding to mTOR but
does not affect Sin1 binding to Rictor (Yang et al., 2006; Rosner and
Hengstschläger, 2008).
mTORC2 activity is enhanced by PIP3 directly (Gan et al., 2011).
This apparent activation might be due to a conformational change in
the PH domain of the mTORC2 substrate Akt, facilitating mTORC2
access to the hydrophobic motif.
mTORC2 activity is upregulated upon inhibition of Epac1, thus
possibly putting cAMP signaling upstream of mTORC2 (Misra and
Pizzo, 2012). Furthermore, mTORC2 might be involved in Notch sig-
naling, as deletion of Rictor in T-cells ablated Notch driven processes
(Lee et al., 2012). mTORC2 activity is reduced in NF2 (neurofibromin
2) deficient cells (James et al., 2012). NF2 or merlin is the tumor
suppressor lost in neurofibromatosis type 2, a non-malignant, inher-
ited cancer disease. TGFβ impinges on mTORC2 activity in the con-
text of epithelial to mesenchymal transition (Lamouille et al., 2012).
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The glucocorticoid-induced leucine zipper protein (GILZ) can bind
mTORC2 and inhibit its activity (Joha et al., 2011). This suggests that
glucocorticoid treatment might be beneficial in cancer therapeutics
by inhibiting mTORC2. The TSC complex might bind mTORC2 lead-
ing to mTORC2 activation (Huang and Manning, 2009; Huang et al.,
2008), however this finding has been questioned by other studies
(Dalle Pezze et al., 2012). mTORC2 signaling is inhibited in Syndecan-
4 null endothelial cells, possibly due to a reduced amount of mTORC2
components associated with lipid rafts (Partovian et al., 2008).
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Figure 2: mTORC2 regulation
While mTORC2 is generally thought to be insensitive to rapamycin,
there are some cell lines that show reduced mTORC2 activity upon
rapamycin treatment. Long-term rapamycin treatment is thought to
sequester free mTOR away as mTOR-FKBP12-rapamycin. Since ra-
pamycin inhibits mTORC1 and thereby translation, synthesis of new
mTOR complex components is reduced and thus, mTORC2 forma-
tion is inhibited (Sarbassov et al., 2006). Inhibition of phospholipase
D (PLD) activity increases the sensitivity of mTORC2 to rapamycin,
8
since phosphatidic acid (PA), the metabolite of PLD, can compete
with rapamycin for FRB binding (Toschi et al., 2009; Fang et al., 2001).
A coherent model of mTORC2 upstream signaling that integrates
these unconnected observations, is currently missing. mTORC2 sig-
naling in general is less studied than mTORC1 signaling, possibly due
to the lack of specific inhibitors. It is also conceivable that mTORC2
regulation is more cell type specific than that of mTORC1, and thus
more difficult to delineate.
1.1.5 Substrates of the mTOR complexes
The majority of mTOR targets are AGC kinase family members such
as Akt, p70 ribosomal kinase 1 (S6K1), SGK1 and PKC. mTOR phos-
phorylates these targets at a so-called hydrophobic motif (HM), that
consists of Phe-X-X-Phe-Ser/Thr-Tyr, and the specific mTOR complex
components (Raptor, Sin1 and Rictor) might be important for recruit-
ing and presenting the targets to mTOR.
1.1.5.1 mTORC1 targets and function
s6k1 Ribosomal protein S6 kinase β-1 (S6K1) promotes transla-
tion initiation and elongation via multiple proteins including eEF3K,
SKAR, CBP80 and eIF4B (Zoncu et al., 2010). Furthermore, mTORC1
via S6K regulates ribosome biogenesis by controlling RNAPI (Mayer
et al., 2004). This couples the energy status of the cell, which is sensed
by mTORC1, to the regulation of cell growth via ribosome biogenesis.
Dietary restriction prolongs life span by inhibiting mTOR complex 1.
S6K1 is implicated in aging and might be the main target in mTORC1
mediated life span regulation (Selman et al., 2009).
S6K1 also mediates a negative feedback loop in mTORC1 signaling.
S6K phosphorylates and thereby inhibits IRS1, which in turn damp-
ens the response of the PI3K pathway to growth factors. This leads
to insulin resistance under chronically high mTORC1 signaling (Um
et al., 2004; Shah et al., 2004; Harrington et al., 2004). Conversely, in-
hibition of the negative feedback loop leads to activation of Akt and
thereby triggers a pro-survival response (O’Reilly et al., 2006). The
negative feedback loop is thought to limit the potential of mTORC1
inhibition in cancer therapeutics.
4e-bp1 eIF4E-binding protein (4E-BP1) associates with mRNAs in
order to control translation initiation and elongation (Ma and Blenis,
2009). Upon phosphorylation by mTORC1, 4E-BP1 dissociates from
eIF4E, thus allowing eIF4G recruitment to the 5’ end of the message.
4E-BP1mediates mTORC1 regulation of proliferation, while S6K1me-
diates mTORC1 regulation of cell size (Dowling et al., 2010).
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autophagy mTORC1 suppresses macroautophagy through phos-
phorylation of ATG13 and ULK1, effectively blocking autophagosome
formation (Hosokawa et al., 2009).
other targets mTORC1 regulates several transcription factors.
Among them, SREBP and PPARγ control lipid synthesis (Kim and
Chen, 2004; Porstmann et al., 2008) while PGC1α and YY1 control
mitochondrial biogenesis and function (Cunningham et al., 2007).
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Figure 3: mTORC1 targets (Laplante and Sabatini, 2012)
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1.1.5.2 mTORC2 targets and function
mTORC2 regulates spatial cell growth and actin organization. This
function of TORC2 is conserved from yeast to mammals (Schmidt
et al., 1996; Jacinto et al., 2004; Sarbassov et al., 2004) and led to an
increased interest in mTORC2 because of its potential role in tumor
cell metastasis and invasion (Zhou and Huang, 2011). The GTPase
Rac1 that binds mTORC2 is possibly involved in regulating the cy-
toskeleton (Saci et al., 2011). The final verdict on how mTORC2 reg-
ulates cytoskeleton organization is far from clear. For example, loss
of mTORC2 has been attributed to both an increase or decrease of
actin stress fiber formation (Jacinto et al., 2004; Sarbassov et al., 2004).
Furthermore, MEFs from Rictor knockout mice failed to show any
obvious alterations in actin organization (Guertin et al., 2006; Shiota
et al., 2006). This discrepancy might come from an adaptation in the
regulation of the cytoskeleton upon long-term mTORC2 inhibition
(Cybulski and Hall, 2009).
Results from C. elegans and tissue-specific knock-out mice indicate
an important involvement of TORC2 in the metabolism of specific
tissues and of the whole body (Gu et al., 2011; Cybulski et al., 2009;
Soukas et al., 2009).
akt mTOR complex 2 in mammalian cells directly phosphorylates
Akt on its hydrophobic motif, S473 (Sarbassov et al., 2005). Phos-
phorylation of Akt by mTORC2 at S473 in combination with phos-
phorylation of Akt by PDK1 in the activation loop at T308 leads to
full Akt activation. Phosphorylation of T308 by PDK1 in Akt does
not depend on prior phosphorylation by mTORC2. mTORC2 might
also phosphorylate the turn motif in Akt at T450 (Facchinetti et al.,
2008; Ikenoue et al., 2008). Interestingly, this phosphorylation, unlike
mTORC2 activity, is not regulated by growth factors. T450 in Akt is
phosphorylated co-translationally by ribosome-associated mTORC2
and is important for Akt stability (Oh et al., 2010). However, it is not
clear why mTORC2 association to the ribosome is growth factor reg-
ulated, while phosphorylation at T450 is not. Furthermore, there are
controversial results concerning direct phosphorylation of Akt at the
turn motif by mTORC2 in vitro (Alessi et al., 2009). An alternative
hypothesis as to how mTORC2 regulates turn motif phosphorylation
is that mTORC2 might control a phosphatase dephosphorylating this
site.
Loss of mTORC2 activity prevents phosphorylation of some, but
not all Akt targets (Yang et al., 2006; Guertin et al., 2006; Soukas
et al., 2009). For example, TSC2 phosphorylation is not changed upon
mTORC2 knockout. This suggests that mTORC2 activated Akt is not
upstream of mTORC1, thus indicating different pools of Akt inside
the cell. S473 phosphorylation of Akt might regulate Akt substrate
specificity rather than absolute activity, thus explaining why not all
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Akt targets are affected by the loss of mTORC2. There is some dis-
crepancy as to whether S473 affects the T308 branch of Akt signal-
ing. A reduction in T308 phosphorylation was reported upon loss of
mTORC2 (Yang et al., 2006), however later studies could not confirm
this observation (Jacinto et al., 2006). It was suggested that in cancer
cells, for example upon loss of PTEN, T308 and S473 phosphorylation
on Akt might become linked (Guertin et al., 2009).
mTORC2 controls glycogen accumulation via Akt mediated phos-
phorylation of GSK3β (Cross et al., 1995). GSK3β phosphorylation
however is not reduced in all cell types upon knockout of mTORC2.
A possible explanation for this comes from the fact that GSK3β can
also be phosphorylated by other kinases such as S6K (Zhang et al.,
2006a).
A more consistently mTORC2-regulated Akt target is the transcrip-
tion factor FOXO1. mTORC2 activated Akt phosphorylates FOXO1,
and thereby inhibits it. FOXO1 affects expression of many genes, one
of which is the Toll-like receptor 4. This might be one way by which
mTORC2 regulates inflammation (Brown et al., 2011). Another tar-
get of FOXO1 is PEPCK, thus making mTORC2 a negative regula-
tor of gluconeogenesis (Puigserver et al., 2003). Interestingly, FOXO1
can also be phosphorylated by SGK1, another direct mTORC2 target
(Brunet et al., 2001), thus making FOXO1 phosphorylation a robust
readout for mTORC2 activity.
Other mTORC2 - Akt targets include Bad (proapoptotic) and AS160
(GLUT4 trafficking) (Brazil et al., 2004; Datta et al., 1997; Kumar et al.,
2010). Phosphorylation of Bad by Akt results in the dissociation of
Bad/Bcl-2 complexes and hence the inhibition of apoptosis. Further-
more, Akt can phosphorylate Bax directly, thereby inhibiting caspase
3 release (Gardai et al., 2004).
sgk1 mTORC2 directly phosphorylates SGK1 (García-Martínez and
Alessi, 2008). This event regulates SGK1 activity toward NDRG1. Ex-
periments in yeast and worms suggest that SGK1 might be the most
important direct downstream target of mTORC2, however it is not
clear yet whether this is also the case in mammalian cells. SGK1
shares some targets with Akt, such as FOXO and GSK3β, but also pos-
sesses unique targets such as Nedd4−2, an ubiquitin E3 ligase (Alessi
et al., 2009). Phosphorylation by SGK1 sequesters Nedd4 − 2 away
from ENaC, the epithelial sodium channel, thus enhancing sodium
transport (Debonneville et al., 2001; Ichimura et al., 2005; Loffing et al.,
2006).
Unlike Akt, SGK1 activity is completely abolished if mTORC2 is
disrupted. Thus, if mTORC2 is knocked out, all SGK1 targets are fully
inhibited, while only a subset of Akt targets is inactive (Jacinto et al.,
2006; Guertin et al., 2006).
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pkc mTORC2 phosphorylates all conventional PKC family mem-
bers and PKC directly at the hydrophobic motif (Ikenoue et al.,
2008; Facchinetti et al., 2008). This phosphorylation controls PKC
activity and stability. The PKC family members diverge at their N-
terminal regulatory region. They do however have overlapping sub-
strates (Newton, 2010). The cytoskeletal defects in mTORC2 knock-
out cells might be partially due to reduced PKC signaling. To this
date, no physiological signals that regulate PKC phosphorylation via
mTORC2 are known. Furthermore, it is currently unclear which pro-
teins mTOR complex 2 controls via PKC. Results from PKC and Akt
knockout mice suggest that Akt is probably a physiologically more
relevant mTORC2 target than PKC (Grahammer et al., 2006; Peng
et al., 2003; Yang et al., 2005; Chen et al., 2006).
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Figure 4: mTORC2 targets
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1.1.6 Tissue-specific functions of mTORC2
The generation of tissue-specific mTOR complex 2 knockout mice
helped greatly in elucidating the diverse roles that mTORC2 plays
in multicellular organisms.
1.1.6.1 Adipose Tissue
Two groups independently reported the generation of adipose tissue
specific Rictor knockout mice (Cybulski et al., 2009; Kumar et al.,
2010). One remarkable phenotype of these mice is their increase in
body and organ size, a phenotype that is even stronger after putting
the mice on a high fat diet. This implies the secretion of a unidenti-
fied factor from the adipose tissue to other organs such as the liver or
the pancreas. Furthermore, the adipose tissue specific Rictor knock-
out mice are hyperinsulinemic and insulin resistant. Adipogenesis is
not affected by mTORC2 knockout.
1.1.6.2 Muscle
Rictor knockout in the muscle was reported by two groups (Bentzinger
et al., 2008; Kumar et al., 2008). While Kumar et al. observed a defect
in glucose transport, Bentzinger et al. reported no metabolic changes
in their mice. Overall, mTORC2 in the muscle seems to play only a sec-
ondary role, compared to mTORC1. This may be due to the fact that
Akt S473 phosphorylation, for unknown reasons, is not completely
abolished upon Rictor knockout in this organ.
1.1.6.3 Brain
Knockout of Rictor in neuronal cells leads to the development of
schizophrenia-like symptoms due to hypodopaminergia (Siuta et al.,
2010). This might explain why certain mental disorders exhibit dereg-
ulation of Akt signaling in the brain and why mTORC2 has been
linked to neurodegenerative disorders such as Alzheimer’s and Parkin-
son’s disease (Beaulieu et al., 2009).
1.1.6.4 β-cells
Knockout of Rictor in pancreatic β-cells leads to a mild hyperglycemia
and glucose intolerance (Gu et al., 2011). Mice are furthermore hy-
poinsulinemic because of a reduced beta cell mass.
1.1.6.5 Liver
Three independent knockout mice for Rictor in the liver have been
described (Hagiwara et al., 2012; Lamming et al., 2012; Yuan et al.,
2012). The main phenotype in these mice is reduced glucokinase and
SREBP1c activity in the liver, leading to constitutive gluconeogenesis,
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impaired glycolysis and lipogenesis. Mice are hyperglycemic, hyper-
insulinemic and hypolipidemic.
1.1.6.6 Immune system
Rictor knockout in double or single positive T cells show that mTORC2
is crucial for the differentiation into T helper 1 (TH1) and TH2 cells,
possibly by regulating STAT signaling (Delgoffe et al., 2009). Partial
Sin1 disruption in mice leads to a defective B cell development, prob-
ably due to the disruption of Akt2 regulated rag1 and il7r expression
(Lazorchak et al., 2010).
1.1.6.7 Kidney
Knockout mice for PRR5 were recently described and interestingly
show no defect in Akt-S473 phosphorylation. However the authors
observed in the kidney a reduced phosphorylation of SGK1 (Pearce
et al., 2011). The physiological importance of PRR5/5L remains un-
clear.
1.1.6.8 Podocytes
Podocyte-specific deletion of Rictor leads only to a mild phenotype.
Mice exhibit stress-induced BSA overload and increased albuminuria
(Gödel et al., 2011).
1.1.7 mTORC2 function in human disease
The mTOR network contains several proteins that are directly in-
volved in tumorigenesis. In the mTORC1 signaling network there are
the tumor suppressors TSC1 and TSC2, LKB1 and the protooncogene
Akt. Loss of the tumor suppressors leads to the development of be-
nign tumors known as hamartomas, whereas Akt amplification has
been linked to more aggressive tumors.
Loss of PTEN, while affecting also mTORC1, seems to primarily
activate mTORC2 and leads to the development and progression of
cancers (Guertin et al., 2009). Indeed, mutations of the PI3K pathway
are present in over 50% of all tumors (Yuan and Cantley, 2008). Fur-
thermore, mTORC2 activity in some cancers might also be due to
overexpression of Rictor (Masri et al., 2007).
While originally only mTORC1 driven tumors could be targeted in
clinical studies because of the mTORC1 specificity of rapamycin and
its analogues (rapalogues), a novel line of inhibitors including dual
mTOR/PI3K inhibitors and mTOR kinase inhibitors, are capable of
targeting mTORC2 driven tumors as well. The rapalogues generally
have only a slight effect on patient outcome and this only on a subset
of cancer types. This has been attributed to inhibition of the negative
feedback loop (O’Reilly et al., 2006; Tabernero et al., 2008). A second
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limitation of this line of treatment is the only recently appreciated
incomplete inhibitory effect of rapamycin on mTORC1 activated 4E-
BP1 (Thoreen et al., 2009; Choo et al., 2008; Feldman et al., 2009),
thus potentially not blocking 4E-BP1 driven cancer cell proliferation
(Dowling et al., 2010). A growing number of clinical trials using the
latest generation of mTOR inhibitors are being rolled out and it re-
mains to be seen whether they will present the anticipated benefit
over rapalogues.
Apart from cancer, mTORC2 has been linked to a number of dis-
eases including diabetes, neurodegeneration and possibly aging (La-
plante and Sabatini, 2012). These relationships will be explored fur-
ther in the context of mitochondria and MAM.
1.1.8 Perspectives in mTORC2 research
Very little is known about how association with ribosomes contributes
to mTOR complex 2 activation. Furthermore, it is unclear how the
relatively large amount of ribosomes compared to mTORC2 can acti-
vate mTORC2 acutely (in other words, why is mTORC2 not always
active?). It should be clarified whether the ribosome-mTORC2 bind-
ing directly activates mTORC2 kinase activity, or whether it merely
allows localization and targeting of mTOR complex 2 to its substrates.
Furthermore, the molecular link between PI3K activity and ribosome-
mTORC2 association is uncharacterized.
The consequence of the known post-translational modifications of
mTORC2 on its activity are still very poorly understood. Another
missing development in the study of mTORC2 signaling are mTORC2
specific inhibitors, that might not only be helpful as research tools but
also in clinical applications.
Finally, the localization of mTORC2 is not well understood, espe-
cially in the context of its activity. Many early studies hypothesized
that mTORC2 activity is mainly restricted to the plasma membrane
(Song et al., 2005), possibly since PDK1 is localized to the plasma
membrane. As will be explored later, mTORC2 has also been phys-
ically or functionally linked to both the endoplasmic reticulum (ER)
and mitochondria.
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1.2 endoplasmic reticulum (er)
1.2.1 Structure and Function
The ER can be divided into 3 major parts that are nevertheless inter-
connected: the nuclear envelope, the rough and the smooth ER (RER
and SER). It is a highly dynamic structure that needs to be remod-
eled according to growth conditions. The RER is usually organized in
sheets and marked by the presence of attached ribosomes, while the
SER is more tubular and convoluted (Voeltz et al., 2002). Most mem-
brane proteins are shared between the SER and the RER. The SER is
only abundant in some cell types and its function includes steroid
synthesis and detoxification. In the following pages, we will mainly
focus on the rough ER.
The ER is an extremely versatile organelle that fulfills many es-
sential functions. The most obvious one is its role in protein synthe-
sis, maturation and quality control. Proteins of the eukaryotic secre-
tory pathway are co-translationally translocated into the ER lumen
by membrane attached ribosomes. The targeting of these mRNAs
is achieved through an SRP (signal recognition particle) dependent
mechanism. SRP binds the emerging peptide from the ribosome upon
recognition of the signal sequence, and then pauses translation. The
complex is then targeted to the translocon complex on the ER, where
translation resumes (Ng et al., 1996). It should be noted however that
there are also SRP independent and posttranslational translocation
mechanisms into the ER. Yeast cells devoid of SRP are viable, and
adapt their growth and secretory pathway to this condition (Siegel,
1995). Interestingly, ER-bound ribosomes can stay bound at the ER af-
ter termination of translation and initiate synthesis of both secretory
and cytoplasmic proteins (Potter and Nicchitta, 2000).
The ER is furthermore an important platform for signaling. Some
enzymatic reactions can occur more efficiently if the dimensionality
of the cytoplasm is reduced by localizing the reaction to the surface
of a membrane. One example is Ras signaling, which occurs not only
at the plasma membrane but also at the ER (Chiu et al., 2002).
The ER is the main calcium store in a cell, and this function will be
discussed later on page 21.
1.2.2 mTORC2 and the ER
mTORC2 was thought for a long time to be associated only with the
plasma membrane, since mTORC2 is activated by PI3K signaling and
PIP3, and since Akt can localize to the plasma membrane through its
PH domain. Recently it became clear however, that mTORC2 signal-
ing might not be restricted to the plasma membrane. In rat liver ex-
tracts, insulin stimulation translocates phosphatidylinositol 3-kinase
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(PI3K) to the ER (Daniele et al., 1999). ER stress inhibits mTORC2
(Chen et al., 2011; Appenzeller-Herzog and Hall, 2012; Hosoi et al.,
2007). The observation that PDK1 mediated T308 phosphorylation is
affected by ER stress indicates an intact PI3K-mTORC2-Akt signaling
at the ER (Yung et al., 2011). A link between mTORC2-Akt signaling
and Grp78 or Bip, an ER chaperone upregulated upon ER stress, has
been suggested by multiple authors (Lin et al., 2011; Yung et al., 2011;
Dai et al., 2010). The exact relationship between mTORC2 signaling
and Bip remains unclear. In Chlamydomonas however, TOR controls
Bip phosphorylation (Díaz-Troya et al., 2011).
In yeast, TORC2 is peripherally membrane associated and is at
or close to the plasma membrane (Wedaman et al., 2003; Sturgill
et al., 2008; Kunz et al., 2000), a localization that coincides with cor-
tical ER (Voeltz et al., 2002). It was shown, albeit inconclusively, that
mTOR contains ER and Golgi localization sequences which may tar-
get mTOR to these organelles (Drenan et al., 2004; Liu and Zheng,
2007). Isolated microsomes (containing ER) harbor mTOR complex
2 activity toward Akt (Hresko and Mueckler, 2005). mTORC2 might
interact with a specific subpopulation of ribosomes, such as ER as-
sociated ribosomes (Zinzalla et al., 2011). In trypanosoma, TORC2
is localized to both the ER and mitochondria (Barquilla et al., 2008).
Finally, a preliminary study suggested that mTORC2 is mainly local-
ized to the ER but failed to show any functional significance of this
localization (Boulbés et al., 2011).
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1.3 mitochondria
1.3.1 Structure and Function
Mitochondria possess an outer and an inner membrane. The inner
mitochondrial membrane (IMM) is folded into the so-called cristae,
thereby increasing the surface area of the IMM. This leads to 2 dif-
ferent compartments inside the mitochondria: the matrix, contain-
ing the genome and enzymes from the TCA cycle, among others;
and the intermembrane space, harboring the components of the elec-
tron transport chain that perfom oxidative phosphorylation. The tra-
ditional view of discrete vesicular mitochondria has shifted in the
past decades to one of a highly dynamic, reticular network of mito-
chondria, that undergo fusion and fission and that are highly motile.
In specialized cells, mitochondria can agglomerate at sites of high
energy demand, such as the Ranvier nodes in neurons (Hollenbeck,
2005).
Mitochondria are central for the energy production from the res-
piratory chain, which takes place on the surface of the inner mem-
brane. Other important functions include lipid oxidation, oxygen rad-
ical production and hormone metabolism (Ferguson, 2002). Their role
in calcium homeostasis, while less studied, is equally crucial (Pizzo
and Pozzan, 2007). Calcium transfer between the ER stores and mito-
chondria occurs preferentially at MAM (see Section 1.4 on page 21).
Mitochondria are well known for their function in the induction
and execution of apoptosis. Initiator caspases such as caspase 8 (acti-
vated for example after binding of the Fas ligand or TNFα, or after
intrinsic induction) cleave the ER cargo receptor BAP31 to form p20,
which induces Drp1/Dlp1 to activate mitochondrial fission (Simmen
et al., 2005; Breckenridge et al., 2003). Mitochondrial fragmentation
offers short-term protection against the propagation of apoptotic cal-
cium waves (Szabadkai et al., 2004). Mitochondrial fragmentation can
also lead to mitochondrial permeabilization and trigger cell death
(Karbowski and Youle, 2003). Mitochondrial permeabilization is me-
diated by the permeability transition pore (PTP), a large pore in the
IMM that, once opened, leads to mitochondrial swelling, outer mem-
brane (OMM) rupture and release of proapoptotic factors such as
cytochrome c into the cytosol.
1.3.2 mTORC2 and mitochondria
mTOR can associate with mitochondria (Desai et al., 2002) and inter-
act with the mitochondrial/MAM protein VDAC1 (Ramanathan and
Schreiber, 2009). mTORC2 phosphorylated Akt (Akt-pS473) can move
to mitochondria (Antico Arciuch et al., 2009). Other studies detected
Akt localization to mitochondria (Bijur and Jope, 2003; Miyamoto
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et al., 2008). Sirt1, which is involved in the regulation of mitochon-
drial function (Gerhart-Hines et al., 2007), stimulates mTORC2 (Rui-
Hong Wang, 2011). Glycerolipids, synthesized by GPAT1 at the mi-
tochondria and possibly the mitochondria associated ER membrane
(Ardail et al., 2003), inhibit mTORC2 activity (Zhang et al., 2012).
PINK1 (PTEN induced kinase 1), a mitochondrial protein linked to
Parkinson’s disease affects mTORC2 function as well (Murata et al.,
2011). Furthermore, a genome-wide shRNA screen showed an ele-
vated mitochondrial dependence in mTORC2-addicted cells (Colombi
et al., 2011). mTORC2 regulates mitochondrial motility (Wang et al.,
2010b). In dorsal root ganglion neurons, NGF activates the PI3K path-
way to modulate mitochondrial docking and reorganization in an
actin dependent way, likely via mTORC2 (Chada and Hollenbeck,
2004).
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1.4 mitochondria associated er membranes (mam)
1.4.1 Discovery and Structure
Figure 5: MAM structure
Close association of the ER with mitochondria has been observed
since the early 1960s (RUBY et al., 1969; Marsh et al., 2001; Mannella,
2006; Mannella et al., 1998; COPELAND and DALTON, 1959; Lewis
and Tata, 1973; Morré et al., 1971). This structure, characterized first
in mammalian cells, was termed mitochondria associated ER mem-
brane (MAM) (Vance, 1990). It was later also isolated from yeast cells
(Gaigg et al., 1995; Zinser et al., 1991). Yeast cells have around 80-110
connections between ER and mitochondria per cell (Achleitner et al.,
1999). Approximately 20% of the mitochondrial surface in a cell is sur-
rounded by MAM in mammalian cells (Rizzuto et al., 1998). This led
to the hypothesis that mitochondrial-ER communication occurs in a
quasi-synaptic structure that is MAM as opposed to vesicular traffic
(Simmen et al., 2005).
Initially, it was thought that MAM would form only at the smooth
ER (Goetz et al., 2007; Wang et al., 2000), but connections with both
SER and RER have been confirmed and the latter type seems to be
predominant depending on the cell type (Csordas et al., 2006; Zhang
et al., 2011). Distances between the two organelles are roughly 10nm
for SER and 25nm for RER. Although the membranes from MAM
originate from the ER, its lipid and protein composition differ from
that of the ER membranes. While less studied, the mitochondrial
membrane at the MAM contact site is also enriched for specific en-
zymes and lipids. Thus, the term MAM is generally used for the ac-
tual contact site between ER and mitochondria (Figure 5, page 21).
21
PACS2 was identified in 2005 to play a role in the maintenance of
MAM (Simmen et al., 2005). PACS2 traffics certain MAM components
to and from MAM. For example, it binds unphosphorylated Bid after
induction of apoptosis, traffics it to MAM and leads to the release
of cytochrome c from mitochondria (Simmen et al., 2005). PACS2 is
also important for the translocation of calnexin to MAM (Myhill et al.,
2008). Interestingly, PACS2 is regulated by Akt phosphorylation, and
this protects cells from apoptosis (Aslan et al., 2009). However it is
unknown whether this phosphorylation affects MAM formation.
One of the MAM tethers is the IP3R-Grp75-VDAC1 complex that
links the ER via IP3R to mitochondria via VDAC1 (Szabadkai et al.,
2006). While both IP3R and VDAC1 are present in the mitochon-
drial and ER membranes respectively, they are highly enriched at
MAM and connected physically via Grp75. IP3R and VDAC1 had
previously been linked to MAM and are central components of ER-
mitochondrial calcium transfer (Gincel et al., 2001; Rapizzi et al., 2002).
VDAC1 also shuttles metabolites such as ATP out of the mitochondria
(Vendelin et al., 2004). Several isoforms of the IP3R exist and they all
function as ER/MAM calcium channels. While IP3R3 is mostly en-
riched at MAM and functions as a tightly regulated calcium release
channel, the other IP3R isoforms, distributed more equally through-
out the ER, might be more important in the basal calcium homeosta-
sis.
A second MAM tether between ER and mitochondria was identi-
fied in 2008. Mitofusin 2 (Mfn2) can form homo or hetero dimers
with Mfn1 in order to connect the ER and the mitochondria (de Brito
and Scorrano, 2008). A third tether called ERMES was discovered in
yeast and does not have a mammalian homolog (Kornmann et al.,
2009). It should be noted that yeast MAM might have different func-
tions shifted more toward lipid trafficking. In yeast, the ER is not
the main calcium store and yeast mitochondria do not possess the
calcium uniporter (de Brito and Scorrano, 2010).
Recently, Rab32 was discovered to be a modulator of MAM forma-
tion that regulates apoptosis by targeting PKA to MAM and mito-
chondria (Bui et al., 2010). Palmitoylation can affect targeting of cer-
tain proteins such as TMX and calnexin to MAM (Lynes et al., 2011).
Information about the proteomic composition of MAM comes from
two MS studies of this subdomain. The authors discovered a num-
ber of proteins at MAM that require further characterization in this
context, e.g. the hexokinase, the TCP1 complex or Bip (Zhang et al.,
2011; Poston et al., 2011). An interesting finding from these studies
was the presence of the translation machinery at MAM. Palmitoy-
lated calnexin is a key component of the ribosome-translocon com-
plex (Lakkaraju et al., 2012), which together with the fact that palmi-
toylated calnexin preferentially goes to MAM (Lynes et al., 2011) sug-
gests a functional role of ribosomes at MAM.
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The signals that control MAM formation are largely unknown. One
study demonstrated that TGFβ exerts a regulatory role toward MAM
formation (Pacher et al., 2008). Ionomycin treatment disrupts MAM,
probably through the sudden release of the calcium stores into the cy-
tosol (Wang et al., 2000; Goetz et al., 2007). MAM formation is a highly
dynamic process (Rizzuto et al., 1998), and a better understanding of
the signaling upstream is strikingly still lacking.
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A selection of recent, MAM-related reviews
Lynes and Simmen (2011) ER function in MAM and PAM
Simmen et al. (2010) Oxidative phosphorylation
Williamson and Colberg-Poley (2009) Viral reproduction at MAM
Pinton et al. (2008) Calcium and MAM
Vance and Shiao (1996) Lipid trafficking at MAM
Grimm (2012) MAM and apoptosis
Schon and Area-Gomez (2010) Neurological disease and MAM
Giorgi et al. (2009) General MAM review
Fujimoto and Hayashi (2011) General MAM review
Hayashi et al. (2009) General MAM review
Glancy and Balaban (2012) Calcium and energetics
Michel and Kornmann (2012) MAM in yeast
Olson et al. (2012) Mitochondrial calcium uptake
Raturi and Simmen (2012) General MAM review
Bravo et al. (2012) ER stress and MAM
Leem and Koh (2012) Diabetes and MAM
Bononi et al. (2012) MAM and calcium
Palmer et al. (2011) Mitochondrial morphology
Patergnani et al. (2011) MAM and calcium
Malhotra and Kaufman (2011) ER stress and MAM
Decuypere et al. (2011) MAM, apoptosis and autophagy
Osman et al. (2011) Phospholipid synthesis at MAM
Baltzer et al. (2010) Mitochondria and nutrients
de Brito and Scorrano (2010) General MAM review
Cheng et al. (2010) Mitochondria and insulin
Stiles (2009) Mitochondria and PI3K signaling
Rizzuto et al. (2009) MAM and calcium
Lebiedzinska et al. (2009) ER connections to organelles
Liesa et al. (2009) Mitochondrial in disease
Vanderheyden et al. (2009) Regulation of IP3R
Pastorino and Hoek (2008) Regulation of HK2-VDAC1
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1.4.2 Function of MAM
MAM has two main functions, namely calcium transfer and lipid syn-
thesis, modification and shuttling. Through these processes, MAM
regulates mitochondrial and ER functions, and apoptosis. While both
calcium release and lipid synthesis also occur elsewhere at the ER,
many key enzymes in lipid biogenesis and ER calcium efflux are clus-
tered around MAM structures, making them hotspots for these pro-
cesses. Traditionally, the ER is thought to control mitochondria via
calcium and lipid transfer. It should be noted though that there is
no clear ER-mitochondrial hierarchy, as MAM disruption affects both
ER and mitochondrial homeostasis. Furthermore, transfer of calcium
and lipids is not unilateral. Certain steps of the lipid synthesis occur
on either side of MAM, and even though the ER is the main calcium
store, calcium reflux from mitochondria to MAM can modulate the
propagation of calcium signaling waves.
Other, less explored functions of MAM include for example the
transport of mitochondrial ATP directly to the ER for oxidative pro-
tein folding (Koumenis et al., 2002). The proteomic studies discussed
above furthermore suggested an important but poorly understood
role of MAM in glycolysis (Zhang et al., 2011).
It should be mentioned that another subdomain similar to MAM
exists in the ER that associates the ER with the plasma membrane
and is termed PAM. This structure is less studied and will not be
discussed here (Pichler et al., 2001; Lebiedzinska et al., 2009).
1.4.2.1 Calcium transfer and apoptosis
The ER is the major calcium store in the cell. ER calcium storage
allows cells and their intrinsic biochemical reactions to become less
dependent on plasma membrane mediated ion fluxes. The calcium
buffering function of the ER allows calcium to function as a second
messenger that is taken up and released under specific conditions
(Koch, 1990). As mentioned above, this occurs at MAM upon stimu-
lation of the IP3R calcium channels. IP3R is stimulated by inositol-3-
phosphate (IP3), which in turn is produced at the plasma membrane
in response to extracellular stimuli. IP3R function is modulated by
many different factors (Hirota et al., 1999). Sigma-1 receptor (Sig-1R)
in a complex with Bip interacts with MAM localized IP3R3 to regulate
MAM function (Hayashi and Su, 2007). Bcl-2 can interact with IP3R
and increase its affinity for IP3 (White et al., 2005). IP3R has a PACS2
binding site, but this function has not been studied in the context of
MAM. ATP can bind IP3R isoforms with different affinities and regu-
late their activity (Maes et al., 2000). Finally, IP3R can be phosphory-
lated by active Akt, thereby inhibiting calcium release and apoptosis
(Szado et al., 2008; Marchi et al., 2008; Khan et al., 2006; Marchi et al.,
2012). Interestingly, Akt was also shown to localize to MAM (Giorgi
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et al., 2010), and the Akt-regulated calcium release occurs predomi-
nantly at the MAM enriched IP3R3 isoform (Marchi et al., 2012).
Changes in ER calcium can affect oxidative protein folding and
hence lead to the induction of the unfolded protein response. While
the concentration of cytoplasmic calcium is generally low (10-100nM),
rapid increases can be observed under particular conditions, rising up
to 2µM due to influx either from the plasma membrane or through
release at MAM. Further exit routes for calcium from the ER are the
ryanodine receptors, which are primarily important in muscle tissue,
and a minor leakage through the translocon pore. Calcium from the
cytosol is reimported into the ER by the Sarco-Endoplasmic Reticu-
lum Ca2+-ATPase (SERCA).
Besides the role of the ER in maintaining cytoplasmic calcium home-
ostasis under normal growing conditions, stimulated calcium release
occurs mostly at MAM in order to regulate mitochondrial function
(Rizzuto et al., 1998). The cytoplasm is a very poor calcium conduc-
tor (less than 10µm2/s) due to its abundance of calcium buffering
proteins. MAM calcium transfer is reminiscent of neuronal signal
transduction and is described as being "quasi-synaptic" (Csordas and
Thomas, 1999). Similar to neuronal transmission, the spatial and tem-
poral patterns of calcium fluxes seem to encode specific cellular re-
sponses (Putney, 1998), and cells can decode not only the amplitude
but also the frequency of such oscillations (Dolmetsch et al., 1998; Li
et al., 1998).
MAM-released calcium flows from the ER side into the intermem-
brane space of the mitochondria. Calcium channels through the outer
mitochondrial membrane (OMM) via VDAC1. It can then enter the
matrix of the mitochondria, however the identity of the IMM calcium
uniporter is still poorly defined (De Stefani et al., 2011b). The influx
of the positively charged calcium ions necessitates the conservation of
the inner membrane potential that would otherwise collapse. VDAC1
is a voltage gated channel that transports ions, nucleotides and cal-
cium. It can change its conformation depending on different con-
ditions, thereby modulating its selectivity and permeability (Giorgi
et al., 2009). Under zero and low (negative or positive) transmem-
brane potentials, VDAC1 has a highly conductive open state with
preference for anionic compounds such as ATP (Shoshan-Barmatz,
2005). Upon VDAC1 closure, the channel exhibits increased perme-
ability for cations and this can lead to an increased mitochondrial
influx of calcium. Permeability toward ATP however is completely
abolished upon closure of VDAC1. VDAC1 closure can be regulated
by different proteins. Association of VDAC1 with hexokinase 1 or 2
(HK1/HK2) promotes cell growth by directly coupling mitochondrial
ATP export to glycolysis (Bryson et al., 2002; Pastorino et al., 2002).
VDAC1-HK2 association is enhanced in certain tumor cells (Wolf
et al., 2011). Detachment of HK2 from VDAC1 induces VDAC1 clo-
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sure, resulting in an increased mitochondrial calcium uptake, an en-
hanced respiration rate (since calcium stimulates the TCA cylce) and
an increased mitochondrial membrane potential. (Stiles, 2009; Chiara
et al., 2008). Interestingly, HK2-VDAC1 binding is stimulated by Akt
mediated phosphorylation of HK2 (Gottlob et al., 2001; Bryson et al.,
2002; Chiara et al., 2008; Miyamoto et al., 2008) and by GSK3β me-
diated phosphorylation of VDAC1 (Pastorino et al., 2005). Even after
termination of the initial MAM calcium pulse, OMM and intermem-
brane enzymes inside mitochondria can "remember" this pulse and
change their respective activities (Lasorsa et al., 2003; Hansford and
Zorov, 1998), an effect that was termed "metabolic memory" (Jouaville
et al., 1999). Calcium stimulates the TCA cycle and ATP synthesis
directly via the pyruvate-, α-ketoglutarate- and isocitrate dehydroge-
nases (Berridge, 2002).
Calcium exits the mitochondria either through VDAC1, through
NCLX or through a Ca2+/Na+ exchanger (Saris and Carafoli, 2005),
and efflux of mitochondrial calcium at MAM might play a role in
the propagation of calcium waves (Boitier et al., 1999; Landolfi et al.,
1998).
Disruption of MAM by depletion of proteins such as PACS2, Sig-1R
or Mfn2 leads to an increase of cytosolic calcium upon IP3R stimula-
tion, as the calcium now leaks into the cytoplasm instead of enter-
ing mitochondria (Simmen et al., 2005; de Brito and Scorrano, 2008;
Hayashi and Su, 2007). Unexpectedly however, Mfn2 disruption also
led to an increase in mitochondrial calcium uptake as these cells pos-
sess larger ER calcium stores and, accordingly, release more calcium
(de Brito and Scorrano, 2008). This increased calcium release might
be a compensation to cover for the decreased MAM calcium transfer.
By modulating calcium homeostasis, MAM regulates ER chaperone
assisted folding of proteins and is thus implicated in ER stress regula-
tion. However MAM released calcium also plays a crucial role in the
induction of apoptosis (Berridge and Bootman, 1998). As mentioned
earlier, MAM-calcium fluxes can trigger different responses depend-
ing on the properties of the calcium flux. Enhanced mitochondrial
calcium influx at MAM is a priming factor that lowers the apoptotic
threshold until a second insult hits the cell and triggers the onset
of apoptosis (Pinton et al., 2001; Szalai et al., 1999). MAM structures
should not be pigeonholed as being either pro- or anti-apoptotic. It is
more accurate to see MAM as a gatekeeper that can mediate or pre-
vent apoptosis dynamically under specific conditions. Accordingly,
disruption of MAM components can both induce or protect from
apoptosis (Giorgi et al., 2012).
MAM mediated calcium influx into mitochondria is important in
the brown adipose tissue in order to maintain and regulate thermo-
genesis (Kuba et al., 2007; de Meis et al., 2010).
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1.4.2.2 Lipids
MAM has an exceptionally high capacity for lipid synthesis (Rusiñol
et al., 1994). MAM is now recognized as being a site of phospholipid
synthesis and transfer (Voelker, 2000; Vance, 1990, 2004). The best
characterized example is phosphatidylethanolamine (PE) biosynthe-
sis. Phosphatidylserine (PS) is synthesized on the ER side of MAM
by phosphatidylserine synthase and is then transported to the mito-
chondrial side where it undergoes decarboxylation to form PE (Ar-
dail et al., 1989; Fagone, 2009) (Figure 5, page 21). Later work also
uncovered the generation of sphingolipids and ceramides at MAM
(Ardail et al., 2003; Bionda et al., 2004). Some of these enzymes are
highly enriched at MAM and serve as MAM markers (ACSL4, PSS1
and PEMT2) (Piccini et al., 1998; Stone and Vance, 2000; Vance et al.,
1997). The role of these lipids are diverse and include regulation of
mitochondrial and ER morphology, and apoptosis (Stiban et al., 2008).
1.4.2.3 MAM function in disease
ACSL4 (Long-Chain Acyl-CoA Synthetase 4, FACL4) is an enzyme
that is highly enriched at MAM and has been linked to Alport syn-
drome, elliptocytosis and mental retardation (Piccini et al., 1998). The
molecular basis for the human neurodegenerative disease NCL (neu-
ronal ceroid lipofuscinosis) is caused by a reduction of lipid traffick-
ing due to MAM disruption (Vance, 1997). Another lipid trafficking
disease is GM1-gangliosidosis, a neurodegenerative disease where
GM1 accumulates at MAM (Sano et al., 2009). Loss of Mfn2 leads to
Charcot-Marie-Tooth neuropathy type 2a (Feely et al., 2011). Sig-1R
is a target for many neurosteroids and neuroleptics (Decuypere et al.,
2011). Presenilins, loss of which causes familiar Alzheimer’s disease
(AD), localize to MAM. Thus, AD could be a disorder of the MAM
(Schon and Area-Gomez, 2010; Zampese et al., 2011). Interestingly,
mTORC2 signaling is also implicated in AD (Pei and Hugon, 2008)
and other parallels between these neurological syndromes and the
phenotypes of defective mTOR signaling exist (Beaulieu et al., 2009;
Siuta et al., 2010; Dummler and Hemmings, 2007; Meikle et al., 2008).
It is unclear why many MAM-linked disease states have neurological
phenotypes. Likely, MAM function is particularly important in neu-
rons (Celsi et al., 2009), as neuronal activity consumes a large amount
of mitochondrially produced ATP (Kann and Kovács, 2007).
MAM plays an important but poorly defined role in viral infec-
tion and replication. Several viral proteins from CMV and HCV lo-
calize to MAM (Bozidis et al., 2008; Sheikh et al., 2008; Zhang et al.,
2011; Horner et al., 2011). Interestingly, CMV infection, which acti-
vates mTORC2 (Clippinger et al., 2011) also increases the amount of
ribosomes at the MAM (Zhang et al., 2011). The HIV protein Nef in-
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teracts with PACS2 (Atkins et al., 2008). Finally, MAVS initiates the
innate immune response at MAM (Horner et al., 2011).
As MAM is involved in the regulation of energy metabolism and
cell death, it is interesting to see that mitostatin, a MAM regulator,
is a tumor suppressor deleted in a variety of tumors (de Brito and
Scorrano, 2010; Vecchione et al., 2009). Grp75 is overexpressed in var-
ious tumors and controls cell proliferation (Kaul et al., 2007). PACS2
is mutated in up to 40% of sporadic colorectal cancer biopsies (Ander-
son et al., 2001). Recently, the tumor suppressor PML was found to
localize to MAM, where it forms a complex with Akt and IP3R, mod-
ulating Akt activity via PP2a (Giorgi et al., 2010). Finally, MAM plays
a role in the pathogenesis of type 2 diabetes (Leem and Koh, 2012),
possibly through its influence on glycolysis (Zhang et al., 2011).
Timeline of important MAM-related publications
Verfaillie et al. (2012) PERK at MAM mediates ER stress
Sebastián et al. (2012) Liver-specific deletion of Mfn2
Fujimoto et al. (2012) Cholesterol regulates MAM
Marchi et al. (2012) Akt regulates calcium release via IP3R3
Poston et al. (2011) MAM proteome
Zhang et al. (2011) MAM proteome
Boulbés et al. (2011) mTORC2 localization to the ER
Horner et al. (2011) HCV replicates at MAM
De Stefani et al. (2011a) VDAC1 relays apoptotic signals
Colombi et al. (2011) Mitochondrial and mTORC2 addicted cells
Murata et al. (2011) PINK1 activates mTORC2
Zinzalla et al. (2011) mTORC2 binds to ribosomes
Zampese et al. (2011) Presenilin is at MAM
Lynes et al. (2011) Palmitoylation signals MAM localization
Giorgi et al. (2010) PML and Akt are at MAM
Bui et al. (2010) Rab32 modulates MAM
de Meis et al. (2010) Thermogenesis by MAM in BAT
Behrends et al. (2010) mLST8 interacts with Grp75
Ramanathan and Schreiber (2009) mTOR is associated to VDAC1
Kornmann et al. (2009) Identification of the ERMES MAM tether
Aslan et al. (2009) Akt phosphorylates PACS2
Stone et al. (2009) DGAT2 and triglyceride synthesis at MAM
Antico Arciuch et al. (2009) Akt-pS473 goes to mitochondria
Sano et al. (2009) Gangliosides and ER stress at MAM
de Brito and Scorrano (2008) Mfn2 is MAM tether
Pacher et al. (2008) TGF-β regulation of MAM
29
Marchi et al. (2008) Akt phosphorylates IP3R
Barquilla et al. (2008) TORC2 at ER and mitochondria
Myhill et al. (2008) PACS2 regulates calnexin distribution
Miyamoto et al. (2008) Akt phosphorylates HK2
Stiban et al. (2008) Ceramides are important for MAM
Bozidis et al. (2008) CMV replicates at MAM
Szado et al. (2008) Akt phosphorylates IP3R
Diaz-Troya et al. (2008) TOR is at ER in Chlamydomonas
Goetz et al. (2007) MAM is regulated by calcium
Hayashi (2007) Sig-1R is at MAM
Szabadkai et al. (2006) IP3R-Grp75-VDAC1 is a MAM tether
Khan et al. (2006) Akt phosphorylates IP3R
Simmen et al. (2005) PACS2 controls MAM
Bionda et al. (2004) Ceramide metabolism at MAM
Ardail et al. (2003) Sphingolipid biosynthesis at MAM
Stone and Vance (2000) PS synthesis at MAM
Szalai et al. (1999) IP3 regulates apoptosis via calcium
Achleitner et al. (1999) MAM quantification in yeast
Csordas and Thomas (1999) MAM is a calcium "synapse"
Landolfi et al. (1998) MAM transfers calcium
Rizzuto et al. (1998) MAM transfers calcium
Mannella et al. (1998) EM tomography of MAM
Vance (1997) MAM involved in lipofuscinosis
Gaigg et al. (1995) Isolation of MAM from yeast
Shiao and Lupo (1995) MAM and phospholipid synthesis
Rusiñol et al. (1994) Lipid synthesis at MAM
Vance (1990) Lipid synthesis at MAM
Morré et al. (1971) EM evidence of MAM
RUBY et al. (1969) EM evidence of MAM
COPELAND and DALTON (1959) EM evidence of MAM
1.4.3 mTORC2 and MAM
As mentioned earlier, several independent lines of evidence suggest a
functional link between the ER, mitochondria and mTORC2 signaling.
MAM, a physical link between ER and mitochondria, presents further
observations that might link it to mTORC2. First, in yeast, TORC2 reg-
ulates ceramides and sphingolipid metabolism (Aronova et al., 2008)
and this regulation might be conserved in mammalian cells (Powers
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Figure 6: Akt signaling at MAM
and Aronova, 2010; Aronova et al., 2008). MAM, on the other hand,
is one of the hotspots of ceramide synthesis and sphingolipid trans-
port (Ardail et al., 2003; Bionda et al., 2004; Rusiñol et al., 1994). Sec-
ond, mTORC2 was isolated from lipid rafts (Partovian et al., 2008).
MAM is also a lipid raft (Poston et al., 2011) and might be the source
for mTORC2 in the lipid raft fractions. Third, the TCP-1 complex,
found at MAM, genetically interacts with TOR2 in yeast (Schmidt
et al., 1996; Poston et al., 2011). Forth, TGFβ inhibits both mTORC2
activity and MAM function. Fifth, PEMT2, a MAM resident protein,
downregulates PI3K - Akt signaling upon overexpression (Zou et al.,
2002). Sixth, Akt localizes to MAM (Giorgi et al., 2010). Seventh, Akt-
pS473 phosphorylation is stimulated by phosphatidylserine, a phos-
pholipid that is produced and enriched at MAM (Stone and Vance,
2000). Finally, the phenotypes of deleting mTORC2 and Mfn2 in the
liver of mice are strikingly similar and include glucose intolerance, hy-
perinsulinemia and enhanced gluconeogenesis (Hagiwara et al., 2012;
Sebastián et al., 2012).
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1.5 aim of the study
mTOR complex 1 localization to lysosomes is crucial for its activa-
tion. mTOR complex 2 localization has been linked to multiple or-
ganelles and is generally less studied. This lack of understanding of
basic mTORC2 signaling is even more striking when considering that
mTORC2 deregulation is implicated in a wide spectrum of human
diseases including cancer and diabetes. As discussed above, mTORC2
has been linked to both the ER and mitochondria, both functionally
and physically. MAM is a central hub in cells where ER and mitochon-
drial functions meet and are synchronized by signaling. Importantly,
MAM formation is not well understood, especially considering the
upstream signaling. For example, insulin regulates ER and mitochon-
drial metabolism, however it is unclear whether it also affects MAM.
Based on the cumulative evidence presented above, I asked whether
mTORC2 could localize to MAM and whether mTORC2 could medi-
ate growth factor signals to MAM.
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2
R E S U LT S
2.1 mtorc2-akt signaling is physically and function-
ally at mam
The following manuscript forms the basis of my PhD thesis. The in-
troduction of the manuscript overlaps partially with the general in-
troduction at the beginning of the thesis (page 1). The cumulative
bibliography from the manuscript and the thesis is given on page 99.
Manuscript submitted to Molecular Cell.
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2.1.1 Abstract
The target of rapamycin (TOR) is a conserved protein kinase and a
central controller of growth. Mammalian TOR complex 2 (mTORC2)
regulates AGC kinase family members and is implicated in various
disorders including cancer and diabetes. Here we report that mTORC2
is localized to the endoplasmic reticulum (ER) and the ER subcompart-
ment termed mitochondria associated ER membrane (MAM). mTORC2
localization to MAM was growth factor stimulated, and mTORC2
at MAM interacted with the IP3R-Grp75-VDAC1 ER-mitochondrial
tethering complex. mTORC2 deficiency disrupted MAM, causing mi-
tochondrial defects including increased respiration, ATP production,
and calcium uptake. mTORC2 controlled MAM integrity and mito-
chondrial function via Akt mediated phosphorylation of MAM associ-
ated proteins IP3R, hexokinase 2 and PACS2. Thus, mTORC2 is at the
core of a MAM signaling hub that controls growth and metabolism.
These findings may offer new therapeutic strategies against mTORC2
driven disease.
2.1.2 Introduction
Mitochondria-associated ER membrane (MAM) is a sub-compartment
of the endoplasmic reticulum that forms a quasi-synaptic structure
with the mitochondria. Its main function is to facilitate the transfer
of lipids and calcium between the two organelles. MAM thereby con-
trols mitochondrial physiology and apoptosis (Csordas and Thomas,
1999; Rizzuto et al., 1998; Duchen et al., 2008). MAM also mediates
ER homeostasis and lipid biosynthesis by harboring chaperones and
several key lipid synthesis enzymes (Osman et al., 2011; Stone et al.,
2009; Ardail et al., 2003; Bionda et al., 2004; Vance, 1990). In mam-
malian MAM, the ER and mitochondria are physically tethered to
each other by the IP3R-Grp75-VDAC1 trimeric complex (Szabadkai
et al., 2006) and dimers of the mitofusin proteins Mfn1 and Mfn2
(de Brito and Scorrano, 2008) (Figure S1A). MAM formation is reg-
ulated by multiple signaling inputs including calcium and possibly
growth factors (Bravo et al., 2012; Bui et al., 2010; Pizzo and Pozzan,
2007; Pawlikowska et al., 2007; Verfaillie et al., 2012; Sebastián et al.,
2012). However, the mechanism(s) that controls MAM formation is
largely unknown other than it involves recruitment of MAM com-
ponents by the MAM resident protein PACS2 (Simmen et al., 2005;
Myhill et al., 2008). Akt, an AGC family kinase that is also found at
MAM (Giorgi et al., 2010), phosphorylates PACS2 (Aslan et al., 2009),
but it remains to be determined whether Akt is involved in mediating
MAM integrity.
Akt, often upregulated in cancer, also phosphorylates hexokinase 2
(HK2) to promote association of HK2 with the MAM protein VDAC1
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(Miyamoto et al., 2008; Gottlob et al., 2001; Pastorino and Hoek, 2008).
This association enables HK2, using ATP exiting mitochondria through
VDAC1, to phosphorylate glucose and thereby stimulate glycolysis
(Stiles, 2009). Conversely, upon inhibition of Akt, HK2 dissociates
from VDAC1 causing VDAC1 closure and increased mitochondrial
membrane potential (Gottlob et al., 2001). This regulation of HK2 by
Akt has been proposed to account for enhanced glycolysis in cancer
cells, also known as the Warburg effect (Wolf et al., 2011). Further-
more, Akt regulates calcium release from MAM by phosphorylating
the IP3 receptor (IP3R), thereby controlling apoptosis (Szado et al.,
2008; Marchi et al., 2008, 2012; Khan et al., 2006). Thus, MAM is in-
creasingly recognized as a signaling hub controlling cell physiology,
and is implicated in a wide spectrum of diseases including cancer,
neurodegenerative disorders, inflammation, and infection (Raturi and
Simmen, 2012).
The Target of Rapamycin (TOR) pathway is a cellular signaling
cascade that, like mitochondria, is present in all eukaryotes (Soulard
et al., 2009; Laplante and Sabatini, 2009a). It integrates and relays sig-
nals from both extra- and intra-cellular sources (e.g., growth factors,
nutrients and cellular energy levels), and thereby instructs the cell to
grow. TOR is found in two structurally and functionally distinct pro-
tein complexes that in mammalian cells are termed mTOR complex
1 (mTORC1) and mTOR complex 2 (mTORC2) (Wullschleger et al.,
2006). mTORC2 comprises mTOR, Rictor, mLST8, Sin1 and protor
(also known as PRR5) (Cybulski and Hall, 2009), and phosphorylates
AGC kinases such as Akt, SGK1 and PKC, all of which are linked to
cancer and diabetes (Oh and Jacinto, 2011; Pearce et al., 2010). Growth
factors activate mTORC2 by promoting mTORC2-ribosome associa-
tion in a PI3K dependent manner (Oh et al., 2010; Zinzalla et al.,
2011). mTORC2 is anti-apoptotic, presumably via its role in phospho-
rylating and activating Akt and thereby inhibiting pro-apoptotic Bad
and FoxO3 (Thedieck et al., 2007; Zinzalla et al., 2011; Sarbassov et al.,
2005; Yang et al., 2006).
Recent findings suggest that mTORC2 is at the endoplasmic retic-
ulum (ER), possibly through interaction with ER-bound ribosomes
(Boulbés et al., 2011; Zinzalla et al., 2011). mTORC2 phosphorylates
Akt at the ER (Hresko and Mueckler, 2005; Boulbés et al., 2011),
and mTOR has been proposed to contain an ER-localization domain
(Liu and Zheng, 2007) and to sense ER stress (Chen et al., 2011;
Appenzeller-Herzog and Hall, 2012). In yeast, TORC2 is peripher-
ally membrane associated and is at or close to the plasma membrane
(Wedaman et al., 2003; Sturgill et al., 2008; Kunz et al., 2000), a local-
ization that coincides with cortical ER (Voeltz et al., 2002). TORC2 has
also been linked to mitochondria. Barquilla et al. reported that TORC2
in trypanosomes is localized to both ER and mitochondria (Barquilla
et al., 2008). mTORC2 regulates the cellular distribution of mitochon-
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dria (Wang et al., 2010b), and mTORC2 activated Akt is associated
with mitochondria (Antico Arciuch et al., 2009; Miyamoto et al., 2008;
Bijur and Jope, 2003). PINK1, a regulator of mitochondrial function,
can activate mTORC2 (Murata et al., 2011). Finally, mTORC2-addicted
cancer cells exhibit enhanced dependence on mitochondria and HK2
(Colombi et al., 2011). Thus, TORC2 has been physically and function-
ally linked to both the ER and mitochondria.
Here we investigated the localization of mTOR complex 2. We show
that ribosome-bound mTORC2 is at the ER, in particular at MAM.
Localization to MAM is growth factor dependent. MAM-associated
mTORC2 activates Akt and thereby controls MAM integrity, mito-
chondrial metabolism, and cell survival. Thus, our findings describe
a critical role for mTORC2 in a MAM signaling hub.
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2.1.3 Results
mTORC2 localizes to mitochondria associated ER-membranes
It has been suggested that mTORC2 is at the ER (Liu and Zheng,
2007; Zinzalla et al., 2011; Boulbés et al., 2011). To examine further
mTORC2 localization, we isolated ER from mouse liver and HeLa cell
extracts by isopycnic flotation (Stephens et al., 2008) and assayed for
mTORC2 by immunoblotting (Figure 8C, page 41). Liver was used
because it is a rich source of ER and because previous studies on
mTORC2 localization were performed only with cultured cells. 30-
60% of mTORC2 (Sin1) was ER associated for liver and HeLa cells,
while only ± 2% of mTORC1 (Raptor) was detected in the ER fraction
for liver cells (Figure 7A, page 40 and Figure 8B, page 41). Previous
studies have suggested that mTORC2 phosphorylates Akt at the ER
(Hresko and Mueckler, 2005; Boulbés et al., 2011). In agreement, we
detected T308- and S473-phosphorylated Akt enriched in the ER frac-
tions (Figure 7A, page 40 and Figure 8B, page 41). Furthermore, we
confirmed that mTORC2 at the ER is intact and associated with ribo-
somes (Figure 7B, page 40). Thus, mTORC2 appears to be localized
to the ER where it phosphorylates Akt.
To characterize further the subcellular localization of mTORC2, we
analyzed Rictor localization by immunofluorescence. Interestingly, the
mTORC2 signal overlapped with mitochondria adjacent to ER (Fig-
ure 7C, page 40 and Figure 8E, page 41), a staining pattern similar to
that of mitochondria associated ER membrane (MAM) proteins (Bui
et al., 2010; Lynes et al., 2011; Horner et al., 2011). We next examined
whether mTORC2 is MAM associated. First, as visualized by electron
microscopy, we detected Rictor at the ER in close proximity to mi-
tochondria (Figure 7D, page 40 and Figure 8D, page 41). Second, as
assayed by subcellular fractionation, Rictor was detected in a crude
mitochondria fraction but not in a fraction of pure mitochondria that
have been stripped of peripheral MAM (Figure 7E, page 40). Third,
we detected approximately 15% of total Sin1 and Rictor in a puri-
fied MAM fraction (Figure 7F, page 40). Finally, we observed that Ric-
tor and Sin1 co-immunoprecipitated with the ER-mitochondria tether-
ing comples IP3R-Grp75-VDAC1 (Figure 9B, page 44 and Figure 10B,
page 45). Grp75 was previously shown in a proteomic study to in-
teract with the mTORC component mLST8 (Behrends et al., 2010)
and mTOR was shown to interact with VDAC1 (Ramanathan and
Schreiber, 2009). Thus, mTORC2 localizes to ER and to the ER sub-
compartment MAM where it interacts with an ER-mitochondria teth-
ering complex.
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Localization of mTORC2 to MAM is stimulated by growth factors
Since mTOR complex 2 activity is insulin-PI3K stimulated, we ex-
amined whether localization of mTORC2 to the ER and in particu-
lar to MAM are regulated by growth factors. We observed 4- to at
least 7-fold higher levels of mTORC2 at the ER (Figure 10A, page
45) and at MAM (Figure 9A, page 44) in liver extracts of mice stim-
ulated with insulin. We also detected enhanced interaction between
mTORC2 and the MAM complex IP3R-Grp75-VDAC1 after insulin
stimulation (Figure 9B, page 44 and Figure 10B, page 45), as assayed
by co-immunoprecipitation. Furthermore, we examined by immunoflu-
orescence the localization of Rictor and the ER marker Hsp47 (Fig-
ure 9C, page 44), and observed a significant increase in co-localization
of Rictor and Hsp47 in cells grown in the presence of serum as com-
pared to serum starved cells. Thus, localization of mTORC2 to the ER
and MAM is stimulated by growth factors.
Since activation of mTORC2 involves binding to the ribosome and
coincides with ER/MAM localization, we examined whether ER/-
MAM localization of mTORC2 requires ribosome binding. Stripping
ribosomes from isolated ER (Figure 10C, page 45) and crude mito-
chondria (Figure 9D, page 44) (consisting of mitochondria and MAM)
reduced the binding of mTORC2 to these organelles. Furthermore,
we observed an mTORC2 dependent increase in ribosomes at MAM
upon growth factor stimulation, suggesting that ribosomes may move
to MAM upon mTORC2 binding (Figure 9E, page 44). The above
observations together suggest that mTORC2 localization to MAM is
dependent on growth factor signaling and interaction with the ribo-
some.
mTORC2 maintains MAM integrity
We next examined whether mTORC2 regulates MAM integrity. First,
we investigated MAM integrity by assaying MAM components in
a crude mitochondrial fraction (de Brito and Scorrano, 2008). The
amounts of MAM proteins IP3R and Grp75 were reduced in a crude
mitochondrial fraction from Rictor knockout cells compared to wild
type cells, although total cellular levels of these proteins were un-
changed (Figure 11A-B, page 46; Figure 12A and G, page 47). As a
second method to assay ER-mitochondria interaction, we monitored
the IP3R-Grp75-VDAC1 complex (Szabadkai et al., 2006; de Brito
and Scorrano, 2008). Less Grp75 and VDAC1 co-immunoprecipitated
with IP3R in Rictor knockout cells (Figure 11C, page 46). Third, we
quantified ER-mitochondrial proximity by analysis of 3D confocal
images of cells co-expressing fluorescent probes for the ER and mi-
tochondria (Lynes et al., 2011; Bui et al., 2010; Simmen et al., 2005;
de Brito and Scorrano, 2008). Both Rictor and Sin1 knockout cells ex-
hibited reduced ER-mitochondrial contact (Figure 11D, page 46; Fig-
42
ure 12B and E, page 47). Fourth, to measure ER-mitochondrial contact
at higher resolution (Csordas et al., 2006; Simmen et al., 2005; de Brito
and Scorrano, 2008), we analyzed electron microscopic images of liv-
ers from Rictor knockout mice and wild type littermates (Figure 12C-
D, page 47). ER-mitochondrial contact sites were reduced ∓40% upon
mTORC2 knockout although total mitochondrial and ER content per
cell were unchanged (Figure 11E, page 46). Furthermore, the mito-
chondrial network was fragmented in primary Rictor knockout hep-
atocytes as compared to wild type hepatocytes (Figure 11F, page 46).
Finally, we examined the role of mTORC2 in MAM dynamics in live
cells. mTORC2 was required for insulin stimulated MAM formation
(Figure 11G, page 46). Thus, mTORC2 mediates MAM integrity and
overall mitochondrial morphology. Furthermore, our results suggest
that insulin signaling controls both localization of mTORC2 to MAM
and MAM integrity.
We next examined if mTORC2 mediates insulin stimulated MAM
integrity via Akt and PACS2. PACS2 is phosphorylated by Akt and is
important for MAM integrity (Simmen et al., 2005; Aslan et al., 2009).
We found that overexpression of wild type PACS2, but not PACS2
mutated at the Akt phosphorylation site (PACS2-S437A), was able to
suppress the defect in ER-mitochondrial contact observed upon Ric-
tor knockdown (Figure 11H-I, page 46). We also observed that both
constitutively active Akt (Akt-S473D) and wild type PACS2 restored
MAM in cells in which mTOR was pharmacologically inhibited (Fig-
ure 12F, page 47). Thus, mTORC2 at MAM appears to control MAM
integrity via Akt and PACS2.
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mTORC2 controls MAM function
To examine further the role of mTORC2 at MAM, we investigated
MAM function in mTORC2 deficient cells. Calcium flux between the
ER and mitochondria occurs mainly at MAM (Patergnani et al., 2011;
Bononi et al., 2012). We looked at ER/MAM calcium release upon
stimulation with exogenously added ATP or upon pharmacological
inhibition of SERCA pumps with thapsigargin (TG). Like MAM de-
ficient cells (de Brito and Scorrano, 2008; Simmen et al., 2005; Bui
et al., 2010), Rictor knockout MEFs displayed increased concentration
of intracellular calcium [Ca2+]i upon either ATP or TG treatment
(Figure 13A-D, page 50). Furthermore, consistent with previous ob-
servations that Akt phosphorylates IP3R and thereby inhibits ER/-
MAM calcium efflux (Khan et al., 2006; Szado et al., 2008; Marchi
et al., 2008, 2012), we found that pharmacological inhibition of mTOR
blocked IP3R phosphorylation (Figure 14D, page 51), and that overex-
pression of constitutively active Akt (Akt-S473D) suppressed the en-
hanced TG stimulated increase of [Ca2+]i in mTORC2 deficient cells
(Figure 13C-D, page 50). Thus mTORC2, via Akt, regulates calcium
release at MAM.
As described previously in MAM deficient cells (de Brito and Scor-
rano, 2008), we also observed an increase in calcium uptake by mi-
tochondria in mTORC2 knockout cells (Figure 13E, page 50 and Fig-
ure 14A-B, page 51). This is counter-intuitive as a reduction in calcium
uptake by mitochondria might be expected in MAM or mTORC2
deficient cells. This seemingly paradoxical observation has been ex-
plained by the fact that MAM deficient cells contain larger ER cal-
cium stores and thus release more calcium for uptake by mitochon-
dria (de Brito and Scorrano, 2008). Accordingly, we also observed
increased ER calcium stores in mTORC2 knockout primary hepato-
cytes and MEFs (Figure 13F, page 50 and Figure 14C, page 51). We
note that enhanced calcium release at MAM can also be attributed to
defective Akt, as shown above (Figure 14D, page 51).
mTORC2 controls mitochondrial physiology
Observations described above (Figure 11F, page 46 and Figure 13E,
page 50) and elsewhere (see Introduction) suggest that mTORC2, like
MAM (Contreras et al., 2010; de Brito and Scorrano, 2010), affects mi-
tochondrial function. We examined mitochondrial function in mTOR
complex 2 deficient cells. Rictor knockout cells exhibited an increase
in routine (basal) respiration (Figure 15A, page 52), mitochondrial in-
ner membrane potential (∆Ψm) (Figure 15B, page 52, Figure 16A-C,
page 53) and ATP production (Figure 16E, page 53). The latter two ef-
fects were suppressed by overexpression of activated Akt (Akt-S473D)
(Figure 15B, page 52; Figure 16B and E, page 53). Akt controls mito-
chondrial potential by phosphorylating hexokinase 2 (HK2) at T473
48
and thereby stimulating translocation of HK2 from the cytoplasm
to the MAM protein VDAC1 (Miyamoto et al., 2008; Gottlob et al.,
2001). We observed that mTOR inhibition blocked HK2-T473 phos-
phorylation in HeLa cells (Figure 15C, page 52). Furthermore, insulin
stimulated recruitment of HK2 to mitochondria, likely MAM, in an
mTORC2 dependent manner in HeLa cells, mouse liver, and MEFs
(Figure 15D-E, page 52 and Figure 16D, page 53). Finally, we found
that overexpression of mutant HK2 containing a phosphomimetic
residue at position 473 (HK2-T473D) suppressed the increased mito-
chondrial potential observed in mTORC2 deficient cells (Figure 15F,
page 52). Thus, mTORC2 controls mitochondrial energy production,
at least in part via Akt mediated regulation of HK2 at MAM.
Mitochondria play a pivotal role in apoptosis. Arachidonic acid in-
duces apoptosis by stimulating the transfer of calcium from the ER to
mitochondria at MAM (Marchi et al., 2012; Rizzuto et al., 2009). Up-
take of calcium by mitochondria can trigger apoptosis by inducing
the mitochondrial permeability transition (MPT) (Gunter and Gunter,
2001). As described above, mTORC2 deficient cells display enhanced
ER/MAM calcium release (Figure 13, page 50). Calcium release was
also enhanced in Rictor knockout MEFs upon arachidonic acid, as
compared to wild type MEFs (Figure 15G, page 52). Furthermore,
an mTORC2 deficiency led to an increase in MPT (Figure 15H, page
52) and elevated levels of cleaved Parp (Figure 15I, page 52). As mea-
sured by Annexin V staining, pharmacologic inhibition of mTOR also
caused an increase in apoptosis that could be suppressed by overex-
pression of wild type PACS2 (Figure 15J, page 52). Thus, mTORC2 at
MAM appears to control several aspects of mitochondrial physiology.
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10µM ATP, visualized by Fura2-AM. (B) Area under the curve
(AUC) of (A) (N=34). (C) Intracellular calcium release in Rictor
knockout and control MEFs, expressing LacZ or Akt-S473D af-
ter stimulation with 10µM thapsigargin, visualized by Fura2-AM.
(D) Area under the curve of (C) (N=16-54). (E) AUC of mitochon-
drial calcium increase in Rictor knockout and control MEFs after
stimulation with 10µM ATP visualized by the cameleon probe
4mtD3cpv (N=20). (F) Area under the curve of intracellular cal-
cium release in Rictor knockout and control MEFs, expressing
LacZ or Akt S473D after stimulation with 10µM ionomycin visu-
alized by Fura2-AM. Scale = arbitrary units. Results are shown
as mean ± SEM and normalized to wild type cells. (? p<0.05, ??
p<0.01, ? ? ? p<0.001)
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Figure 14: Supplementary: mTORC2 controls MAM function. (A) Basal
mitochondrial calcium levels in Rictor knockout and control
MEFs, arbitrary units (N=3). (B) Peak influx of mitochondrial cal-
cium levels after ATP stimulation in Rictor knockout and con-
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Figure 15: mTORC2 controls mitochondrial function. (A) Respiration of
MEFs (N=4). (B) Mitochondrial potential of MEFs expressing
LacZ, Akt-WT or Akt-S473D (N=3). (C) Akt mediated phospho-
rylation of HK2. (D) Localization of HK2 in MEFs. (E) GFP-
HK2 localization to mitochondria is inhibited by mTOR inhibition
(PP242). (F) Mitochondrial potential of Rictor KO MEFs is rescued
by HK2 T473D (N=3). (G) AUC of intracellular calcium release
of MEFs after treatment with 80µM arachidonic acid (N=67-70).
(H) Mitochondrial pore permeability transition. Absence of mito-
chondrial calcein signal indicates permeability transition in Ric-
tor knockdown HeLa cells. (I) Parp levels in MEFs. (J) Apoptotic
HeLa cells expressing PACS2-WT or PACS2-S437A as determined
by Annexin V staining (n=3).
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Figure 16: Supplementary: mTORC2 controls mitochondrial function. (A)
Mitochondrial potential of shCtrl or shRictor expressing HeLa
cells (N=3). (B) Mitochondrial potential of Rictor knockout or con-
trol primary hepatocytes expressing either LacZ or Akt-S473D
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p<0.001)
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2.1.4 Discussion
We show that mTORC2 is physically associated with MAM, and that
mTORC2-Akt signaling mediates MAM integrity and function. First,
mTORC2 localizes to MAM in a growth factor stimulated manner.
Second, mTORC2 is required for MAM integrity and function, at least
in part through Akt phosphorylation of PACS2, IP3R and HK2. Third,
via its role in MAM, mTORC2 also affects ER and mitochondrial func-
tions, in particular calcium flux and energy production. Accordingly,
we find that mTORC2 disruption phenotypically mimics a MAM de-
ficiency. Thus, MAM appears to be an mTORC2 signaling hub.
mTORC2 is activated by association with the ribosome and thereby
directly couples the growth potential of the cell, i.e. the ribosome pool,
to the control of cell growth and survival (Zinzalla et al., 2011). We
find that mTORC2 exerts this control at least partly at MAM. Electron
microscopy studies (Csordas et al., 2006; Lebiedzinska et al., 2009;
RUBY et al., 1969) and proteomic profiling (Zhang et al., 2011; Poston
et al., 2011) of MAM suggest that ribosomes are present at this ER
subdomain, although the function of MAM localized ribosomes is
unclear. Zhang et al. (Zhang et al., 2011) reported an increase in the
number of ribosomes at MAM after CMV infection, a virus that is
known to activate mTORC2 (Clippinger et al., 2011). Finally, calnexin,
a MAM enriched chaperone (Lynes et al., 2011; Myhill et al., 2008),
interacts with PACS2 and anchors ribosomes at the ER and possibly
MAM (Lakkaraju et al., 2012; Chevet et al., 1999). It remains to be
determined whether calnexin is indeed involved in localization of
ribosomes to MAM or in mTORC2 signaling.
The presence of mTORC2 and phosphorylated Akt at MAM sug-
gests that mTORC2 phosphorylates Akt (S473) at MAM. Akt is gener-
ally thought to be localized to the plasma membrane, upon binding of
its PH domain to PIP3, where it is phosphorylated by PDK1 at T308
and by mTORC2 at S473. However, previous studies have reported
active Akt at mitochondria and MAM (Giorgi et al., 2010; Antico Ar-
ciuch et al., 2009; Miyamoto et al., 2008; Bijur and Jope, 2003). Further-
more, insulin stimulation induces translocation of phosphatidylinos-
itol 3-kinase (PI3K), the enzyme that catalyzes PIP3 formation, from
the plasma membrane to the ER (Daniele et al., 1999). Finally, we
find PDK1 and T308 phosphorylated Akt at MAM (Figure 9A, page
44). Thus, there appears to be spatially distinct mTORC2 signaling
pathways. Interestingly, there are at least three different mTORC2s
containing a distinct Sin1 isoform (Frias et al., 2006).
Here we report that hepatocytes from liver specific Rictor knock-
out mice are defective for MAM. Hagiwara et al. recently reported
that Rictor knockout mice have whole body metabolic defects (Hagi-
wara et al., 2012). Interestingly, liver specific knockout of Mfn2, a key
MAM protein, confers a whole body phenotype strikingly similar to
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that of liver specific Rictor knockout. Both knockout mice exhibit in-
creased gluconeogenesis, hyperinsulinemia and glucose intolerance
(Sebastián et al., 2012). This strong metabolic phenotype is consistent
with the fact that the liver relies heavily on MAM function and that
MAM mediates glucose metabolism (Rusinol et al., 1994; Zhang et al.,
2011). The mTORC2 deficient liver is also defective in lipogenesis
due to a failure in Akt dependent activation of SREBP1c (Hagiwara
et al., 2012). It is conceivable that mTORC2 regulated MAM integrity
is important for the activation of SREBP1c, as ceramide synthesis af-
fects SREBP translocation and as MAM is important for ceramide
metabolism (Bionda et al., 2004; Worgall et al., 2004). The reduction
in liver weight upon mTORC2 knockout (Hagiwara et al., 2012) can
be explained by an increase in apoptosis due to a MAM deficiency.
Furthermore, a previously reported whole genome shRNA screen re-
vealed that mTORC2 addicted cancer cells are dependent on mito-
chondrial function and in particular HK2 (Colombi et al., 2011). Thus,
MAM appears to be a particularly important hub for mTORC2 sig-
naling in the control of growth and metabolism.
In summary, we demonstrate that mTORC2 can localize to MAM,
where it controls growth factor mediated MAM integrity, calcium
flux, and mitochondrial physiology. mTORC2 controls these processes
via Akt, which in turn regulates PACS2, IP3R and HK2 at MAM. The
combined action of these substrates affects energy metabolism and
cell survival. While the role of MAM localized mTORC2 in disease
remains to be clarified, it is tempting to speculate that there could be
beneficial effects of novel therapeutic interventions that specifically
target mTORC2 localized to MAM.
2.1.5 Material and Methods
Cell culture
HeLa and inducible Rictor knock-out MEFs were cultured, transfected,
stimulated and harvested as described previously (Jacinto et al., 2004;
Cybulski et al., 2012; Thedieck et al., 2007). Briefly, cells were seeded
and grown for 48 hours in DMEM supplemented with 10% serum
(basal conditions). Cells were starved of serum for 14 hours unless
noted otherwise before re-stimulation with 100nM insulin (Sigma) for
10 minutes.
Primary hepatocytes: Cells were isolated using previously described
protocol (Hagiwara et al., 2012).
mTORC2 knockdown: HeLa cells were infected with lentiviruses
carrying shControl or shRictor (TRC library, Sigma Aldrich) at MOI
of 0.1. Cells were selected after 24h with 1µg/ml puromycin for 1
week, then subcloned and kept under puromycin selection.
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Transfection: Transfection was performed using X-tremegene HD
(Roche) using per 10cm dish 1ml Optimem (Gibco), 6µg plasmid
DNA and 18µl transfection reagent.
Plasmids
GFP-tagged HK2 was kindly provided by Alenoush Vartanian. HA-
tagged mouse HK2 (HA-HK2) in pcDNA3.1 was kindly provided
by Nobuyuki Tanaka (Ando et al., 2010). HK2-T473D was generated
from HA-HK2 by mutagenesis (Zheng et al., 2004) using the follow-
ing primers GAAGgacCTGGAGTCTCTGAAGC and CAGgtcCTTCTG-
GCGGGCCC. Mutagenesis was sequence verified. Adenoviral LacZ,
Akt-WT and Akt-S473D were produced as previously described (Hagi-
wara et al., 2012). PACS2-HA and PACS2-S437A-HA (Aslan et al.,
2009) were obtained from Prof. Gary Thomas. 4mtD3cpv was kindly
provided by Dr. Amy Palmer and Roger Tsien.
Protein lysates, immunoprecipitations
Protein extracts were prepared as previously described (Thedieck
et al., 2007; Jacinto et al., 2004), resolved on SDS-PAGE and trans-
ferred to nitrocellulose membranes (Protran, Whatman). Immunopre-
cipitation and immunoblotting were performed as previously describ-
ed (Thedieck et al., 2007; Jacinto et al., 2004; Zinzalla et al., 2011).
Subcellular fractions were normalized to protein concentration prior
to loading. Films were scanned on CanoScan 9000F and signals were
quantified using densitometry functions of the FIJI application. Per-
centage of different proteins in a given fraction were calculated as
protein densitometry multiplied by volume and protein concentra-
tion of that fraction divided by the amount in the total extract.
Subfractionation: ER was isolated by isopycnic flotation using pre-
viously described protocol (Stephens et al., 2008; Lerner et al., 2003).
Crude and pure mitochondrial extracts, MAM isolation: Performed
as previously published (Wieckowski et al., 2009).
Ribosome stripping: Experiment was performed as previously pub-
lished (Adelman et al., 1973).
Phosphorylation status of IP3R: HeLa cells were starved for 14h,
treated with 500nM PP242 or DMSO for 20 minutes and stimulated
with 20% FCS for 20 minutes. IP3R was immunoprecipitated and
blots were probed with anti-IP3R or anti-phospho-Akt-Substrate anti-
body.
Phosphorylation status of HK2: HeLa cells were transfected with
HK2-HA 48h prior to experiment. HeLa cells were starved for 14h,
treated with 500nM PP242 or DMSO for 20 minutes and stimulated
with 20% FCS for 20 minutes. Blots were probed with anti-HA or
anti-phospho-Akt-Substrate antibody.
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Insulin stimulation of mice: Mice were starved for 14-16h over night,
then injected IP with 4.5mg/kg insulin or saline 30 minutes prior to
sacrifice. Refed mice were starved for 14-16h over night, then refed a
standard chow diet for 2h.
Microscopy
Immunofluorecence: For organelle labeling experiments, cells were
infected 24h prior to harvest with baculovirus expressing ER-GFP or
Mito-RFP (BacMAM, Life Technologies). Cells were seeded on 12mm
glass slides 24h before experiment. Cells were washed in PBS, fixed
with 37◦C 4% paraformaldehyde for 2 minutes, washed in PBS 2
times, treated with 0.1% Triton X100 for 10 minutes at room tempera-
ture, blocked in 3% BSA for 1h at room temperature. Primary antibod-
ies were added over night at 4◦C (1:50 for anti-rictor, 1:200 for anti-
HSP47), washed 3 times in PBS at room temperature and incubated
with secondary antibodies (anti-rabbit-Alexa647 1:200, anti-mouse-
Alexa488 1:200) for 2h at room temperature. Slides were washed 3
times in PBS and mounted in Mowiol mounting medium (2.4g Mowiol
4-88 Calbiochem, 6g glycerol, 6ml water, 12ml 0.2M Trix pH8.5, 2.5%
w/v [1,4,-diazobicycli-[2.2.2]-octane Sigma-Aldrich). Fluorescence was
measured on LSM510 or LSM710. Colocalization (Pearson’s correla-
tion coefficient) was measured with Imaris application using auto-
matic thresholding.
Electron microscopy: Embedding protocol: Mouse liver was cut
into small pieces of 1-2mm and fixed with 0.1M phosphate buffer con-
taining 3% formaldehyde and 0.3% glutaraldehyde for 30min at RT
and with fresh fixative overnight at 4◦C.Then samples were washed
with PBS 3x30min. Dehydratation was done at 4◦C in 50%,70%,90%
methanol/PBS each for 1h. Infiltration with LR gold was done accord-
ing to the manufacturer’s instructions (LR gold London Resin com-
pany). Polymerization was done at -10◦C for 24h. Sections of 75nm
were collected on Formvar/ carbon coated Ni-grids. Sections were
stained for 15min with 4% uranyl-acetate and contrasted with lead-
citrate for 60sec., visualized by a Philips EM100 electron microscope.
Images were cropped for individual hepatocytes using Adobe Pho-
toshop. Cell parameters including ER length and mitochondrial size
were calculated using FIJI application.
Statistical Analyses
Data were expressed as average ± SEM of at least three independent
experiments. Unpaired t test was used to determine differences be-
tween two groups. Significance was judged when p < 0.05.
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Animals
Mice were generated as previously described (Hagiwara et al., 2012).
All experiments were performed in accordance with federal guide-
lines and were approved by the Kantonales Veterinäramt of Kanton
Basel-Stadt.
Chemicals
Antibodies: mTOR, Akt, Akt pS473, Akt pT308, S6, PDI, Insulin re-
ceptor, Lamp1, Rictor IB, VDAC1, IP3R, Grp75, PDK1, Rheb, HA,
Mfn2, RXRXXpS/T (9611), HK2, CoxI, cleaved Parp from Cell Sig-
naling; Sin1, Raptor, Rpl26 from Bethyl; PGK1, ACSL4, from Santa
Cruz; PEMT2, Rictor IF from Protein Atlas; Rab32 from Sigma; Cal-
nexin from BD Bioscience; CoxIV from Invitrogen; Hsp47 from Enzo
Life Science; Rictor EM from Abcam (ab104838); Rab5 antibody was
obtained from Martin Spiess; Rictor IP antibody was obtained from
Markus Rüegg.
Chemicals: PP242 (Chemdea); insulin, ionomycin, thapsigargin and
arachidonic acid (Sigma); Fura 2 AM (Invitrogen).
Metabolic measurements
Mitochondrial potential measurements were performed using MitoPT
- TMRM (ImmunoChemistry Technologies LLC) following the manu-
facturers’ instructions on a Biorad Biomek NK and statistical analysis
was performed using FlowJo 9.4.
Permeability transition: Calcein staining was performed using the
Image-iT LIVE Mitochondrial Transition Pore Assay Kit (I35103) (In-
vitrogen) following recommended protocol.
Mitochondrial Ca2+: MEFs were transiently transfected with the
ratiometric cameleon probe 4mtD3cpv targeted to the mitochondrial
matrix 48h before the experiments. Ratiometric images of Ca2+ sig-
nals were obtained using a microscope (Axio Observer, from Zeiss)
equipped with the Lambda DG4 illumination system (Sutter Instru-
ment Company, Novato, CA, USA). Cells were illuminated at 440 nm
(440AF21; Omega Optical) through a 455DRLP dichroic mirror, and
emission was collected alternatively at 480 nm (480BP10; Omega Op-
tical) and 535 nm (535AF26; Omega Optical), using a cooled, 12-bit
CCD camera (CoolSnap HQ, Ropper Scientific, Trenton, NJ, USA). Im-
age acquisition and analysis were performed with the Metafluor 6.3
software (Universal Imaging, West Chester, PA, USA). Experiments
were performed at room temperature in Hepes-buffered solution con-
taining (in mM): 135 NaCl, 5 KCl, 1 MgCl2, 1 EGTA, 10 Hepes, 10
glucose, pH adjusted at 7.45 with NaOH.
Intracellular Ca2+: Cells were plated 48h before experiment on Lab-
Tek chamber slides (Thermo). Chambers were washed loaded for 30
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minutes with HBSS plus calcium, 10% FCS and 1µM Fura2 AM (Invit-
rogen). 10 minutes before measurement and medium was replaced by
adding calcium free HBSS (Sigma) and Fura-2 signal was measured as
described previously (de Brito and Scorrano, 2008). Signal was cap-
tured and processed on Zeiss Cell Observer light microscope. Area
under the curve was calculated with Graphpad Prism 5 using base-
line correction. Stimulations were performed with 10µM ATP, 10µM
thapsigargin, 80µM arachidonic acid or 10µM ionomycin.
To measure the oxygen consumption in MEF cells, we used the
Oxygraph-2k (Oroboros Instruments). After centrifugation and resus-
pension in IMDM medium (Sigma-Aldrich) without any additions,
the measurement of Rictor wildtype MEFs and Rictor knockout MEFs
was performed in parallel chambers using 2 million cells per cell line.
Following inhibitors and uncouplers have been used: Oligomycin at
2µM; FCCP at 1µM; Rotenon at 0.5µM (manufacturer); Antimycin A
at 2.5µM (manufacturer). Routine, leak, ETS and ROX were calculated
as described before (Gnaiger, 2008).
Apoptosis: Annexin V Alexa Fluor 488 (Invitrogen) measurements
were performed as previously described (Colombi et al., 2011).
ATP: ATP was quantified using CellTiter-Glo Luminescent assay
(Promega).
Statistics: Student’s T Test was calculated using QuickTTestX 1.0
application.
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2.2 additional results
The following sections deal with supplementary findings that could
not be included in the manuscript. Some of the data presented here
are preliminary and should be regarded as starting points for further
investigations into the role of mTORC2 at MAM.
2.2.1 mTORC2-ribosome-enriched mRNAs
2.2.1.1 Introduction
As mentioned previously, ribosomes bind mTORC2 and are impor-
tant for its activation (Zinzalla et al., 2011). As there are many more
ribosomes than mTORC2 in a cell, we asked whether mTORC2 asso-
ciates only with a subset of ribosomes. It should be noted that these
results came chronologically before the discovery of mTORC2 local-
ization to the ER/MAM. This project initially followed the study of
the upstream mechanisms governing ribosome mediated mTORC2 ac-
tivation. However at a later stage, this interesting aspect, that still de-
serves further study, was not followed up on and we instead focused
more on the downstream function of mTORC2-MAM localization.
Ribosomal heterogeneity is a term that was first used in the 1970s
to describe different functional classes of ribosomes defined by differ-
ent structural composition (Bickle and Howard, 1973). Newer studies
suggest that structurally different ribosomes can translate different
mRNAs (Mauro and Edelman, 2002; Komili et al., 2007). On a more
fundamental level, ribosomes are classified into ER-translating or cy-
tosolic ribosomes. ER associated ribosomes are generally thought to
be structurally identical to cytosolic ribosomes. The emergence of
the translated signal peptide recruits the signal recognition particle
(SRP). This leads to the translocation of the message into the ER lu-
men. Some reports also suggest the possibility of SRP-independent
translation at the ER (Potter and Nicchitta, 2000). After termination of
translation, fully assembled ribosomes can stay bound at the ER and
initiate translation of secreted and cytosolic proteins (Adelman et al.,
1973; Potter and Nicchitta, 2000). It is estimated that roughly 50%-90%
of the cellular ribosomes are associated to the endoplasmic reticulum,
depending on the cell type and growth conditions (Stephens et al.,
2005).
2.2.1.2 Results
To identify if mTORC2 is associated with a subset of ribosomes, we
performed a microarray-based study to identify mRNAs that either
co-purified with whole ribosomes or with mTORC2-associated ribo-
somes. We assumed that even though mTORC2 is activated by asso-
ciation to ribosomes in a translation-independent manner, the nature
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of these potentially enriched messages could help elucidate mTORC2
activity.
free mTORC2 
soluble proteins
mTOR
ribosomal pellet
{
Y
Y
IP mTORC2
IP ribosome
{
RNA isolation 
and analysis
GeneChip
A
mTOR
ribosome
associated 
mTORC2 
mTOR
[R
N
A
] /
 m
oc
k
0
5
10
15
20
25
30
IP mock IP mTORC2 IP ribosome
Serum starved  + + +
Serum stimulated  - + +
Wortmannin  - + -
[R
N
A
] /
 m
oc
k
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
IP mTORC2 IP mTORC2 IP mTORC2
B
C
*
*
*
ns
Figure 17: Purification of mTORC2 - associated mRNAs. (A) Schematic
representation of the working protocol. Cells are homogenized,
and lysates are centrifuged through a sucrose cushion. Riboso-
mal pellets including ribosome associated mTORC2 are recov-
ered and used for immunoprecipitations. (B) Amount of RNA re-
covered from mTORC2 and ribosome immunoprecipitations, nor-
malized to mock IP. (C) Quantification of RNA recovered from
an mTORC2 immunoprecipitation under different growth condi-
tions.
Ribosome-associated mTOR complex 2 can be purified from riboso-
mal pellets (Zinzalla et al., 2011). To specifically enrich for ribosome-
associated mTORC2, we performed immunoprecipitations from pu-
rified ribosomal lysates of mTORC2 (Sin1) or of ribosomes (Rpl26)
(Figure 17A, page 62). First, we quantified the amount of RNA co-
purified in mTORC2 or ribosome immunoprecipitations relative to a
mock IP (Figure 17B, page 62). Immunoprecipitation of mTORC2 co-
purified 4 times more RNA than a mock IP, and immunoprecipitation
of ribosomes co-purified 27 fold more RNA than the mock IP. Second,
we performed the experiment after serum starvation and restimula-
tion in presence or absence of the PI3K inhibitor wortmannin. We find
a PI3K-dependent increase of co-immunoprecipitated RNA and thus
mTORC2 ribosome interaction under serum stimulation (Figure 17A,
page 62). These observations are in agreement with previous studies
(Zinzalla et al., 2011).
To identify potentially enriched or excluded mRNAs from mTORC2-
ribosomes, we loaded an equal amount of co-purified mRNA from
either mTORC2-IP or ribosome-IP on Affymetrix microarrays. 6740
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Annotation Cluster 1 Enrichment Score: >150
Category Term Count % PValue Bonferroni
SP_PIR_KEYWORDS transmembrane 1198 73 <1.0E-250 <1.0E-250
SP_PIR_KEYWORDS membrane 1257 76 <1.0E-250 <1.0E-250
UP_SEQ_FEATURE transmembrane region 1196 73 <1.0E-250 <1.0E-250
GOTERM_CC_FAT GO:0016021~integral to membrane 1217 74 1.1E-215 4.6E-213
GOTERM_CC_FAT GO:0031224~intrinsic to membrane 1233 75 5.6E-211 2.4E-208
Annotation Cluster 2 Enrichment Score: 112.91
Category Term Count % PValue Bonferroni
SP_PIR_KEYWORDS endoplasmic reticulum 330 20 2.2E-166 1.2E-163
GOTERM_CC_FAT GO:0005783~endoplasmic reticulum 390 24 5.4E-118 2.3E-115
GOTERM_CC_FAT GO:0044432~endoplasmic reticulum part 162 10 1.49E-56 6.41E-54
Annotation Cluster 3 Enrichment Score: 109.02
Category Term Count % PValue Bonferroni
SP_PIR_KEYWORDS signal 725 44 1.1E-170 6.2E-168
UP_SEQ_FEATURE signal peptide 725 44 7.7E-170 2.6E-166
SP_PIR_KEYWORDS disulfide bond 473 29 2.66E-52 1.5E-49
UP_SEQ_FEATURE disulfide bond 447 27 3.7E-46 1.25E-42
Figure 18: Cluster analysis of mTORC2 enriched mRNAs. mRNAs found
enriched on mTORC2 ribosomes were analyzed for functional
clustering by the online application DAVID. Three clusters with
highest scores are shown.
messages of a p-value <0.05 could be identified in both immunopre-
cipitates and the ratio of the mRNA signal from the mTORC2 IP di-
vided by the signal from the ribosome IP was plotted on a histogram
(Figure 19B, page 64). As expected, a majority (72%) clustered around
a ratio of 1, meaning that they were equally likely to be found on
an mTORC2-associated ribosome as any other ribosome. Of special
interest to us were the mRNAs enriched more than 1.5 fold, which
comprised 1770 messages (26%).
We analyzed this list of mTORC2-ribosome enriched mRNAs with
the online tool DAVID (The Database for Annotation, Visualization
and Integrated Discovery v6.7) and found among the highest enrich-
ment clusters the terms "transmembrane" (72% of the enriched mes-
sages), "endoplasmic reticulum" (24%) and "signal peptide" (44%). All
these terms are a common feature of endoplasmic reticulum trans-
lated mRNAs (Figure 18, page 63). These results were further con-
firmed by qPCR validation (Figure 19B, page 64).
Of note, there was only a minority of mRNAs excluded from mTOR
complex 2-associated ribosomes (2%), containing among others a clus-
ter of cytosolic proteins. Whether this unequal distribution of en-
riched / excluded mRNAs reflects a biological phenomenon such
as the translation of cytosolic proteins at the endoplasmic reticulum
(Lerner et al., 2003) remains unknown.
We also analyzed the mTORC2-enriched mRNAs for any motifs
that might be enriched in their respective UTRs. These mRNAs were
enriched in UNR binding sites (1.8 fold enriched, UNR complex = as-
sembly platform for formation of decay mRNA-protein complex), K-
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box, GY-box and BRD-box (2.4 fold enriched, miRNA seed sequences
enriched in Notch target genes) and IRES (1.4 fold enriched, internal
ribosome entry site). The significance of these motifs in the context of
mTORC2 is unknown.
Complete dataset in Excel format will be available online under
http://edoc.unibas.ch .
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Figure 19: mTORC2 - ribosome enriched mRNAs (A) Histogram of the ra-
tios of the mRNA signal from an mTORC2 ribosome divided by
the signal of that same mRNA from a ribosome IP. Messages are
considered mTORC2-ribosome enriched/excluded if their ratios
exceed 1.5 fold change. (B) Confirmation of microarray data by
qPCR. Ratios of ER and cytosol translated mRNAs were checked
in immunoprecipitates from independent experiments. Grey bars
indicate results from qPCR, black bars indicate original ratios
from the microarray experiment.
2.2.1.3 Discussion and outlook
We show that mRNAs that code for ER translated messages can be
co-purified from mTORC2-associated ribosomes. Our results confirm
that mTORC2 associates to ribosomes in a growth factor-PI3K reg-
ulated manner. Furthermore, these data provide more evidence for
mTORC2 localization to the ER and mTORC2-ribosome interaction
at the ER.
Chronologically, these were the first data that indicated mTORC2
presence at the ER, even before our biochemical approaches (Fig-
ure 7B, page 40) or an independent study (Boulbés et al., 2011) con-
firmed this localization. In the spirit of generating a more focused
manuscript, we decided to omit this part and present it here.
One question is how do these data fit in with MAM localization
of mTORC2. mTORC2 localizes to MAM (Figure 7F, page 40), and
is bound to ribosomes at this site (Figure 9D, page 44). Furthermore,
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we found that ribosomes move to MAM upon insulin stimulation in
a growth factor dependent manner (Figure 9E, page 44). Very little
information is available on ribosomes and their function at MAM.
Initially, it was thought that MAM forms only at the smooth ER,
but as discussed earlier, these claims have been refuted. A functional
role for ribosomes at MAM might exist in the context of spatially
regulated translation, similar to local translation that is observed at
neuronal synapses (Wang et al., 2010a). It is up to speculation as to
what these locally translated messages might be, however it is inter-
esting to note that some viruses such as the cytomegalovirus (that
is also know to affect mTORC2 signaling) change the composition
of MAM and actively recruit the translation machinery to MAM, by
an unknown mechanism (Zhang et al., 2011). A hypothetical exam-
ple for MAM restricted translation could be mitochondrial proteins,
as the co-translational import of proteins into mitochondria has been
suggested previously (Ahmed and Fisher, 2009). It should be noted
though that there were no obvious clusters in the mTORC2 enriched
mRNAs that might point to localized translation of MAM or mito-
chondrial proteins.
Several more steps could be investigated to complete this part of
the project. One open question for example is if mTORC2 is involved
in the translation of the mTORC2-ribosome enriched mRNAs. We an-
alyzed some potential candidates for their respective protein levels
and found no difference in liver-specific mTORC2 knockout lysates
compared to wild type littermates (data not shown). As noted ear-
lier, this does not exclude the possibility that mTORC2 is involved in
regulating local translation of these messages.
It would be interesting to isolate ribosomes and their respective
mRNAs specifically from MAM. This could be done in a growth fac-
tor dependent manner in combination with knocking out mTORC2.
mRNAs could then be normalized to total mRNAs in order to look
for any locally translated messages at MAM.
One unknown factor is the sequence of events leading to mTORC2
binding to the ER-translating ribosomes. Two possibilities exist: 1)
mTORC2 binds these ribosomes in the cytoplasm and then moves
along to the ER (e.g. by interacting with the SRP complex) or 2)
mTORC2 heads to the ER independently of ribosomes and there it
engages in mTORC2-ribosome interaction. Even though we observed
mTOR-Srp14 interaction by masspectrometry in an earlier study (Adiel
Cohen, unpublished), the results from a more detailed study of mTOR
complex 2-SRP interaction were inconclusive (data not shown). We
propose a model where mTORC2 goes to the ER/MAM and there
engages in ribosome interaction.
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2.2.1.4 Material and Methods
ribosome purification This protocol needs to be performed
on ice or at 4 degrees celsius in absence of any RNases. Use 10 −
30 80% confluent 15cm plates of cells. For stimulations, cells were
serum starved for 16h, pretreated with wortmannin for 5min (100nM)
and stimulated with insulin 100nM 5 − 10min. Wash 2x cold PBS,
trypsinize, collect, spin 2500g 5m, add 20ml PBS cycloheximide (CHX,
100µg/ml) for 5m, count cells, spin 800g 5m, add 100µl buffer A per
107 cells, mix by pipetting 5 times p1000, wait 20m on ice, dounce
until 90% lysis, pellet 8000g 5m, measure protein concentration. Layer
500 − 600µl on top of 11ml 30% sucrose cushion, run at 39k g 17h.
Invert tubes to empty sucrose, wipe with kimwipe. Pellets should be
visible as clear glassy material attached to the bottom. Add 300 −
500µl of buffer B, resuspend carefully, dounce 5x, measure protein
concentration.
Buffer A: 100mM KCl, 5mM MgCl2, 100mM Hepes, 0.3% CHAPS,
1mM DTT, 100U/ml RNAsin, Roche Complete Protease Inhibitors
Buffer B: 50mM Tris pH 7.5, 150mM NaCl, 2mM MgCl2, 1mM DTT,
0.3% CHAPS, 100U/ml RNAsin, Roche Complete Protease Inhibitors
immunoprecipitation from ribosomal pellets To riboso-
mal lysate, add 4µg antibody, incubate with mixing end over end at
4 degrees 3h. Add 50µl of blocked microspheres in buffer B 1h. Wash
4x buffer B. Elute by adding 1ml RLT buffer, follow RNeasy Micro kit
(QIAgen) instructions for purification of RNA, elute with 14µl water,
check concentration by nanodrop, freeze at -80 degrees or use imme-
diately.
Microspheres: Use 1µm Protein-A coated microspheres (Bangs Labs)
following the manufactures’ guidelines, pellet 10000g 2m, wash 2x,
resuspend in buffer B plus 5% BSA plus 10µg/ml yeast tRNAs.
microarray analysis Microarray analysis was performed after
quantification of mRNA and quality check in the Life Sciences Train-
ing Facility by Philippe Demougin on Affymetrix Human Gene 1.0
Array.
cluster analysis The following settings were using while do-
ing the cluster analysis on the mTORC2 enriched mRNAs: DAVID
http://david.abcc.ncifcrf.gov. Background List HuGene-1.0-st-v1.
Classification Stringency Medium. Kappa similarity: Similarity Term
Overlap 3, Similarity Threshold 0.5. Classification: Initial Group Mem-
bership 3, Final Group Membership 3, Multiple Linkage Threshold
0.5.
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2.2.2 MAM integrity is important for mTORC2
2.2.2.1 Introduction
Since ribosome association is important for mTORC2 activation and
since mTORC2 is catalytically active at the ER and MAM, one ob-
vious question is whether MAM localization is itself important for
mTORC2 activity. One can imagine two possible scenarios where
MAM integrity could be upstream of mTORC2: mTORC2 kinase ac-
tivity might be affected by MAM, or mTORC2-substrate exhibition
might depend on MAM, both leading to a similar outcome.
A possible hint that mTORC2 activity might indeed be affected un-
der conditions where MAM integrity is reduced comes from the ob-
servation that the liver-specific knockout of Mfn2 leads to very similar
phenotypes as liver specific Rictor deletion (as mentioned above) (Se-
bastián et al., 2012). Mfn2 knockout leads to a reduction of Akt S473
phosphorylation, indicating reduced mTORC2 activity. The authors
concluded that elevated ER stress in these mice might inhibit insulin
signaling.
2.2.2.2 Results
To see whether MAM formation is important for mTORC2 activity, we
analyzed mTORC2 function in Mfn1/Mfn2 double knockout MEFs
(Mfn dKO) that have a strong reduction in MAM formation (de Brito
and Scorrano, 2008). The mitofusin proteins are important for mito-
chondrial fusion and form a molecular tether between the ER and
the mitochondria in order to maintain MAM function (de Brito and
Scorrano, 2008).
We find that in Mfn dKO cells, Akt S473 phosphorylation is severely
reduced compared to control MEFs, while mTORC1 or PI3K activity
is not affected (Figure 20A, page 68 and Figure 21A, page 69). This
was confirmed by Mfn2 or Grp75 knockdown (Figure 20D, page 68).
A similar observation on Akt S473 was recently reported in a liver-
specific Mfn2 knockout mouse and reported to be due to an increase
in ER stress (Sebastián et al., 2012), however we observe no change in
ER stress levels in the Mfn dKO MEFs (Figure 21B, page 69). mTORC2
complex integrity is not affected in the Mfn dKO (Figure 20B-C, page
68). Concomitant with the defect in MAM formation in the Mfn dKO
cells is the reduction of mTORC2 levels in the crude mitochondrial
extract but not in purified ER of Mfn dKO cells (Figure 20F, page
68 and Figure 21C, page 69). Furthermore, we treated cells with ion-
omycin that leads to ER fragmentation and MAM disruption (Park
et al., 2000; Goetz et al., 2007) and find a reduction in mTORC2 but
not mTORC1 activity (Figure 20D, page 68).
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Figure 20: mTORC2 activity depends on intact MAM. (A) Insulin stimu-
lated Akt-pS473 is reduced in Mfn1/2 dKO MEFs. (B) mTORC2
integrity is unchanged in Mfn dKO MEFs. (C) mTORC2 compo-
nents are unchanged in Mfn dKO MEFs. (D) mTORC2 activity is
reduced upon knockdown of Grp75 or Mfn2. (E) Ionomycin treat-
ment, disrupting ER/MAM integrity, inhibits mTORC2 but not
mTORC1 activity. (F) Mfn dKO MEFs show a reduction of MAM
and mTORC2 components in a crude mitochondrial fraction com-
posed of MAM and mitochondria.
2.2.2.3 Discussion and outlook
We observe that mTORC2 is both upstream and downstream of MAM.
Previous results from a whole genome shRNA screen already showed
the importance of mitochondrial function for mTORC2 addicted can-
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show no induction of ER stress response. (C) Mfn dKO MEFs
show no reduction of mTORC2 components at the ER, indicating
that mTORC2 can associate to the ER even if MAM is disrupted.
cer cells (Colombi et al., 2011). It may seem counterintuitive that one
process is both upstream and downstream of a protein. However, the
TOR signaling network presents multiple feedback loops (Efeyan and
Sabatini, 2010) and many processes are both upstream and down-
stream of either one of the two TOR complexes, e.g. sphingolipid
metabolism (Roelants et al., 2011; Tabuchi et al., 2006; Aronova et al.,
2008), autophagy (Yu et al., 2010; Jung et al., 2010), amino acid sig-
naling (Schmidt et al., 1998; Avruch et al., 2009) and ER stress (Tabas
and Ron, 2011; Kato et al., 2012).
The molecular logic behind this additional loop might be a protec-
tion mechanism for the cell to endure starvation. Reduced mTORC2
signaling under these circumstances could cause a decrease in MAM
in order to protect cells from apoptotic calcium fluxes from the ER
while increasing the mitochondrial potential to stabilize the cellular
energy levels, keeping the cells ”locked” in a pre-apoptotic and anti-
tumorigenic state. By the same logic, prolonged mTORC2 inactivity
or disruption might cross this threshold and induce apoptosis, thus
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presenting mTORC2 with the role of a buffer between apoptosis in-
duction and execution. It will be interesting to see if under chronic
mTORC2 activation, observed in many cancers, there is an increase
in MAM formation and function, switching the cellular energy pro-
duction from mitochondrial respiration to glycolysis.
We also show that mTORC2 activity is dependent on intact MAM
and ER. This on the other hand might reflect a new sensory input to
inform mTORC2 about the apoptotic stimuli that are transferred to
the mitochondria via MAM.
We used Mfn1/2 double knockout MEFs. One might argue that
Mfn2 (the predominant MAM tether) single knockout MEFs should
be used instead. We tried to replicate our findings by knocking down
Mfn2 with siRNA and could reduce Akt S473 phosphorylation (Fig-
ure 20D, page 68). The single knockout MEFs have been described,
but are not commercially available in Europe. We were unsuccessful
in obtaining these cells from the lab that originally generated them
(Chen et al., 2005).
An interesting observation comes from the fact that even though
there is reduced mTORC2 at MAM in the Mfn2 knockout cells (be-
cause of reduced MAM formation), mTORC2 levels at the ER are
unaffected (Figure 20F, page 68 and Figure 21C, page 69). This indi-
cates that mTORC2-MAM and not ER localization is important for
its activity, thus underlining that mTORC2-MAM localization is not
only a consequence of its ER localization, but that mTORC2-MAM
association plays a functional role.
As discussed above, several pools of mTORC2might exist. A global
reduction of mTORC2 activity upon MAM disruption suggests that
MAM localized mTORC2 might be predominant in this particular
cell type or for the subset of mTORC2 targets observed. Alternatively,
MAM localized mTORC2 might be mostly responsible for short-term,
insulin mediated signaling, while other pools of mTORC2 might be
more important for maintaining basal mTORC2 activity.
Liver-specific knockout mice for Mfn2 and mTORC2 share many
phenotypes such as reduced Akt signaling, glucose intolerance and
increased gluconeogenesis (Sebastián et al., 2012; Hagiwara et al.,
2012). It is difficult to distinguish if this phenotype in the Mfn2 knock-
out mice is due to reduced mTORC2 activity or if on the other hand
the phenotype in the Rictor knockout mice is due to reduced MAM
formation. Cyclic pathways are inherently difficult to delineate, how-
ever one could imagine trying to rescue the phenotype of the Mfn2
knockout mouse by injecting it with adenoviral Akt S473D, thereby
mimicking mTORC2 activity. The opposite approach, that is trying to
restore MAM formation in the mTORC2 knockout liver, is more dif-
ficult, as it has been shown that overexpression of MAM tethers can
lead to a disruption in MAM function.
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The phenotypes of the liver-specific mTORC2 knockout mice were
described to be due to a deficiency in glucokinase and SREBP1c activ-
ity (Hagiwara et al., 2012). We show in our study that hexokinase 2 at
MAM is regulated by mTORC2 via Akt. Glucokinase (HK4) is closely
related to HK2 and might be regulated in a similar manner. Indeed
GK and hexokinase localize to MAM (Zhang et al., 2011). It is not ex-
actly known how mTORC2 regulates SREBP1 maturation. Ceramides
play a role in SREBP1c activation and we found that ceramide levels
are reduced in mTORC2 knockout hepatocytes (Figure 25A, page 77).
mTORC2 activity is disrupted in Mfn1/2 dKO MEFs. However, we
did not answer whether this is due to reduced kinase activity of
mTORC2 or whether it is a lack of substrate availability that causes
this defect, since Akt also localizes to MAM (Giorgi et al., 2010).
A study from the Pandolfi laboratory suggested that Akt at MAM
can be inhibited through the action of PP2a and PML (Giorgi et al.,
2010). Considering this, it is surprising to see that Akt phosphoryla-
tion upon MAM disruption is decreased and not increased. We per-
formed some preliminary mTORC2 kinase assays in the Mfn deficient
MEFs and saw no change in mTORC2 activity toward a recombinant
Akt substrate (data not shown). This suggests that mTORC2 substrate
availability might be the cause for the decreased Akt phosphorylation
in the Mfn dKO MEFs. However, as we immunoprecipitated mTORC2
from whole cell lysates for this assay, we cannot exclude that other po-
tential pools of mTORC2 which might not depend on MAM integrity
compensated for this loss of MAM. For future experiments, mTORC2
should be isolated from the MAM fraction to measure its activity
upon Mfn deletion.
Phosphatidylserine (PS) can modulate mTORC2 activity toward
Akt (Huang et al., 2011). We see that in the mTORC2 knockout livers,
PS levels are reduced (Figure 25A, page 77). Since PS is synthesized at
MAM, this might present one potential mechanism by which reduced
MAM affects mTORC2 activity.
An interesting approach to further explore mTORC2 activity at
MAM would be to target mTORC2 specifically to the ER or to MAM
in order to test if this affects its activity. We tried targeting mTORC2
to the ER by a so called TA anchor, a tail that anchors proteins in
a posttranslational manner to the cytosolic side of the ER. We intro-
duced this tail into both Rictor and different Sin1 isoforms. However,
this was unsuccessful, possibly because introduction of the tags pre-
vented these artificial mTORC2 components from integrating into the
complex (data not shown). It is inherently difficult to introduce tags
into mTOR complex components, since they commonly lead to the
exclusion of that component. In further experiments, we generated
fusion proteins between mTORC2 and MAM or ER marker proteins.
The outcome of these experiments was not successful either (data
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not shown). A third approach of manipulating MAM targeting of
mTORC2 by palmitoylation will be discussed below.
2.2.2.4 Material and Methods
cell culture Mfn1/2 dKO MEFs were purchased from ATCC
and grown in DMEM, supplemented with 30% FCS, 2mM glutamine,
1X penicillin-streptomycin, 50µg/ml uridine. Cells proliferate slowly
compared to their WT control MEFs and should be kept around 10−
50% confluency.
treatment Cells were serum starved for 4h and stimulated with
insulin 100nM for 10min. Ionomycin treatment was 0.5µM for 10min
in HeLa cells.
knockdowns siRNA smartpools were purchased from Dharma-
con. We used 100nM siRNA per 6 well using Fugene HD (Roche)
transfection reagent and protocol. Protein levels were assessed after 3
days.
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2.2.3 Differential localization of Sin1 isoforms
2.2.3.1 Introduction
In order to reconcile previous reports of plasma membrane localiza-
tion of mTORC2 (Saci et al., 2011) with our own observations, we
hypothesized that there could be different pools of mTORC2. Three
different mTORC2 complexes have been described previously (Frias
et al., 2006). These complexes are defined by 3 Sin1 isoforms. Since
mTORC2 might form dimers, this leads to a diversity of potential
combinations. No functional differences are known between the Sin1
isoforms in vivo. Sin1.5 (the shortest isoform) lacks the Ras binding
and PH domain and its activity does not respond to insulin in vitro.
Sin1.2 lacks the Ras binding domain. The exact function of the Ras
binding domain is not known, as previous studies were performed on
tagged Sin1 isoforms that could not integrate into mTORC2 (Schroder
et al., 2007).
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Figure 22: Sin1 isoforms and modifications. Alignment of the 5 different
Sin1 isoforms and their respective domains.
2.2.3.2 Results
It had been previously observed that a shorter isoform of Sin1 was
enriched in ribosomal pellets (Vittoria Zinzalla, unpublished results).
We could confirm this observation, especially when comparing cyto-
plasmic extracts to ER extracts (Figure 23, page 74) and MAM (data
not shown).
We had difficulties in identifying the exact Sin1 isoform that is en-
riched at the ER and MAM. We overexpressed different tagged Sin1
isoforms that had been previously published, but they were either
not expressed in our hands (Frias et al., 2006) or were migrating at
a different molecular weight than predicted (data not shown). What
is clear though is that it is one of the shorter isoforms that is en-
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Figure 23: Sin1 isoforms. Sin1 isoforms in different subcellular lysates.
riched at the ER and MAM, thus limiting the possible isoforms to
Sin1.2 and Sin1.5. Alternatively, the isoform might be differentially
post-translationally modified at different organelles, thus changing
its migration pattern.
We were interested as to what could be the reason for this differ-
ential localization, especially in the context of MAM localization. The
only signal that is known to target a protein preferentially to MAM is
palmitoylation. This post-translational modification targets proteins
such as TMX and calnexin to MAM in a regulated manner (Lynes
et al., 2011). 2-bromopalmitate, an inhibitor of palmitoylation inhibits
Akt S473 phosphorylation (Watson et al., 2011).
Position Peptide Score Cutoff
Sin1.1 103 ERQNQIKCKNIQWKE 0.324 0.196
231 NDNVSAYCLHIAEDD 0.778 0.408
440 DSDLLCACDLAEEKS 0.889 0.408
Sin1.2 103 ERQNQIKCKNIQWKE 0.324 0.196
231 NDNVSAYCLHIAEDD 0.778 0.408
404 DSDLLCACDLAEEKS 0.889 0.408
Sin1.5 103 ERQNQIKCKNIQWKE 0.324 0.196
231 NDNVSAYCLHIAEDD 0.778 0.408
322 SQKVSGACD****** 3.083 0.951
Figure 24: Predicted palmitoylation of Sin1 isoforms. Sin1 isoforms were
analyzed for potential palmitoylation sites by the online applica-
tion CSSPalm 3.0.
We analyzed the different Sin1 isoforms and mTORC2 components
with a palmitoylation prediction algorithm termed CSSPalm 3.0
(http://csspalm.biocuckoo.org/online3.php). There were no signif-
icant hits discovered in any mTORC2 subunits except for Sin1.5, which
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had a high of 3.083 (in the same range as positive control sites) (Fig-
ure 24, page 74). Scores under 1 are generally more difficult to inter-
pret. This predicted palmitoylation needs to be confirmed experimen-
tally in the future.
2.2.3.3 Discussion and outlook
We show preliminary data that there might be an enrichment of cer-
tain Sin1 isoforms at the ER. We have not included these observations
in the main manuscript or developed them further because many nec-
essary tools are still missing. We lack reliable Sin1 antibodies and
functional Sin1 isoform specific expression vectors. The study of dif-
ferent pools of mTORC2 definitely deserves a thorough analysis that
exceeds the scope of this project.
We tried re-expressing different Sin1 isoforms in Sin1 knockout
MEFs generously provided by Estella Jacinto. However, these MEFs
were not viable in our hands for more than 2-3 passages regardless
of Sin1 transfection, thus limiting any further study. The design of
Sin1 isoform specific siRNAs or antibodies is theoretically possible
and might be of help in future studies.
The non-expressing Sin1 isoform plasmids obtained from Addgene
(Frias et al., 2006) were resequenced in order to determine the cause
for the lack of expression. No mutations in the coding sequences were
found. The isoforms will be subcloned in a different expression vector
in the future.
Specific tools for the identification of palmitoylation on a given site
exist and include radioactive labeling with palmitate or non radioac-
tive labels that require masspectrometry-based identification. These
tools should be used in the future to confirm the possible palmitoyla-
tion of Sin1.
2.2.3.4 Material and Methods
sin1 isoforms Isoforms were visualized using Geneious software.
sin1 palmitolyation prediction The online palmitoylation
prediction server CSSPalm was used (http://csspalm.biocuckoo.org/
online3.php). Threshold was set to medium stringency.
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2.2.4 mTORC2 regulates lipid trafficking at MAM
2.2.4.1 Introduction
As stated before, the two main arms of MAM function are calcium
and lipid trafficking between the ER and mitochondria. The calcium
related MAM deficiencies in the mTORC2 knockout cells have been
described earlier (Figure 13, page 50). Here we focus on the lipid
compositions of different endomembranes in the mTORC2 knockout
hepatocytes. As published previously, liver-specific Rictor knockout
mice are hypolipidemic (Hagiwara et al., 2012). Here we isolated dif-
ferent subcellular organelles and purified their respective phospho-
lipids, which were then subjected to MS analysis or detection by TLC.
2.2.4.2 Results
The following lipids were detected and quantified by masspectrome-
try: SM (sphingomyelin), PC (phosphatidylcholine), PE (phosphatidyl-
ethanolamine), PI (phosphatidylinositol), PS (phosphatidylserine), PA
(phosphatidic acid), PG (phosphatidylglycerol) and Cer (ceramides).
Massspectrometry allows further subclassification of these phospho-
lipids but for simplicity, we show here only the average of each phos-
pholipid class. Results are filtered for lipid species that were at or
below the detection limit or that were not present in one of the frac-
tions (total, ER, MAM, Mitochondria). Ratios of the lipid concentra-
tion from the knockout divided by the wildtype extracts are shown.
Extracts were pooled from 3 different mice.
The total extracts from liver-specific mTORC2 knockout mice show
a striking deficiency for most phospholipids (Figure 25A, page 77). A
ratio of 1 indicates that the total levels of this lipid are not changed
in the extract from the knockout mouse.
Since we were primarily interested in the distribution and traffick-
ing of phospholipids, we also compared the respective lipid levels
from MAM and mitochondrial fractions (Figure 25B, page 77). A ratio
of 1 indicates a similar amount of a lipid species in its respective or-
ganelle between knockout and wild type. A lower ratio indicates that
more of this lipid is present in the wildtype fraction. We can see from
these results that many of the phospholipids are depleted from Rictor
knockout mitochondrial extracts and enriched in knockout MAM ex-
tracts. This suggests that MAM-mitochondrial trafficking is reduced
in these cells. Our findings were confirmed using TLC separation of
the abundant phospholipids PS and PC (Figure 25C, page 77).
Complete dataset in Excel format will be available online under
http://edoc.unibas.ch .
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Figure 25: Lipid synthesis and trafficking in Rictor knockout livers. (A)
Phospholipids isolated from total liver extracts of liver specific
Rictor knockout mice relative to their controls. (B) Phospholipids
isolated from MAM and mitochondrial extracts of liver specific
Rictor knockout mice relative to their controls. Ratios > 1 indicate
accumulation of the lipid in that specific organelle upon Rictor
knockout. (C) PS and PC levels in MAM or mitochondrial frac-
tions as resolved by TLC. Values show densitometric measure-
ments of lipid intensities, normalized to wild type levels.
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2.2.4.3 Discussion and outlook
In accordance with our previous results, we show that lipid traffick-
ing between ER and mitochondria is deficient upon Rictor knock-
out. Furthermore, total phospholipid levels are reduced in the Ric-
tor knockout cells, further underlining the importance of mTORC2 in
lipid metabolism (Laplante and Sabatini, 2009b). It will be important
for future research to distinguish whether the general defect in phos-
pholipid synthesis in the mTORC2 knockout is caused directly by
the defect in MAM. Evaluation of organelle lipid compositions from
MAM deficient tissues (e.g. Mfn2 knockout livers) will be helpful in
making this distinction.
These data are to our knowledge the first in depth study of MAM
lipid composition. Unfortunately, very little information about MAM/
mitochondrial lipid composition from other MAM deficient cells are
available, so it is difficult to put our results into the context of a MAM
deficiency.
As seen in Figure 5, page 21, the steps in phospholipid synthesis
carried out at the ER side of MAM are PA to PS and PE to PC. PS to
PE is carried out on the mitochondrial side of the MAM junction. We
see an accumulation of all of these lipid species at MAM of mTORC2
deficient cells, while observing a decrease in their levels at mitochon-
dria, respectively. We are uncertain if PE, also accumulated at MAM
of Rictor knockout cells, is synthesized at mitochondria or at another
site such as the ER.
The results from the MS analysis presented here should be consid-
ered as preliminary. Even though we pooled extracts from 3 different
mice from each genotype, the entire detection should be repeated
with more samples in the future. Furthermore, more lipids species
should be analyzed independently by TLC separation.
We present the measurements as the average levels for each class
of lipid species. For example, 48 different subspecies of PS can be
detected (PS(31:1)-PS(44:2)). Furthermore, we filtered out low abun-
dant species that represented only minorities of their respective class.
A more detailed evaluation of the different subspecies of these lipid
classes might provide new insights into their function in the context
of mTORC2 or MAM.
2.2.4.4 Material and Methods
organelle isolation Purification of different organelles was
performed as previously described(Wieckowski et al., 2009).
phospholipid extraction Protocol was performed as required
by the lipidomics facility (http://www.k-state.edu/lipid/lipidomics/
index.htm)
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Use glass tubes with Teflon-lined screw caps. To 0.8 parts cells/tis-
sue (homogenized) in aqueous solution, add 1 part chloroform and
2 parts methanol. Shake well, add 1 part chloroform and 1 part wa-
ter. Shake, centrifuge at low speed for 5-10 min. Remove the lower
layer. Add 1 part chloroform, shake, centrifuge, remove the lower
layer. Add 1 part chloroform, shake, centrifuge, remove the lower
layer. Wash the combined lower layers once with a small volume 1 M
KCl and once with a small volume of water. Fill tubes with nitrogen,
store in freezer; evaporate the solvent, fill the tubes with nitrogen,
and ship on dry ice. If you have trouble with emulsions, you may
have to add some KCl or other salt to the extraction.
phospholipid analysis Analysis was performed by the Kansas
Lipidomics Research Center (KLRC) at Kansas State University. Sam-
ples were normalized to dry lipid weight.
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2.2.5 mTORC2 controls body temperature
2.2.5.1 Introduction
We were interested in the consequences of the MAM defects caused
by mTORC2 disruption on whole body physiology. Unfortunately,
very little work has been done toward generating tissue-specific knock-
out mice for MAM proteins such as Grp75, PACS2 or IP3R3. It is likely
that there are differences in the importance of MAM function between
tissues such as the liver, the muscle and particularly the brain because
of neurological disorders.
To test if mTORC2-MAM regulation is a general phenomenon not
restricted to the liver and or cultured cells, we asked whether mTORC2
knockout in the adipose tissue also leads to MAM related pheno-
types. MAM in white adipose tissue supposedly plays only a minor
role compared to the liver. The Ad-Cre driver used to generate the
adipose-specific mTORC2 knockout mice however is also expressed
in the brown adipose tissue. The ER and mitochondria in this spe-
cific organelle play a very central role in thermogenesis. MAM in the
brown adipose tissue has been linked to the regulation of thermoge-
nesis (Kuba et al., 2007; de Meis et al., 2010).
We asked therefore if the core body temperature is affected in the
adipose-specific Rictor knockout mice; a phenotype previously un-
characterized in these mice (Cybulski et al., 2009).
2.2.5.2 Results
The mice were 37 weeks of age, on a standard chow diet and under
anesthesia for 5 minutes before the core body temperature was mea-
sured. As can be seen in Figure 26, page 80, adipose-specific Rictor
knockout mice (AdRicKO) displayed an average reduction of 1.5◦C
in their core body temperature when compared to their wild type
littermate controls (AdRicWT) (3 mice per group).
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Figure 26: Body temperature in AdRicKO mice versus wildtype litter-
mates. AdRicKO mice show an average drop of 1.5 degrees Cel-
sius in their core body temperature.
80
2.2.5.3 Discussion and Outlook
We observe a reduction in the body temperature of AdRicKO mice.
We wanted to correlate these findings with a reduction in MAM for-
mation that we would expect upon mTORC2 knockout in this tissue.
However, due to the small size of the brown adipose tissue, analy-
sis of MAM integrity by biochemical fractionation is unfeasable. In-
stead we tried to evaluate any potential MAM deficiencies by electron
microscopy. Unfortunately, we failed to establish a protocol that pre-
served the integrity of MAM during embedding. Together with our
collaborator Cristina Baschong, we will try to further optimize this
protocol in the future. Alternatively, we could measure the mitochon-
drial uncoupling of this tissue in order to see if the the reduced body
temperature is caused by the defect in the brown adipose tissue (BAT)
uncoupling that might be due to a MAM deficiency. Of note, no dif-
ference in the amount of BAT was detected between wild type and
Rictor knockout (Cybulski et al., 2009). The AdRicKO mice have an
increase in body size, however, there is no correlation between body
size and body temperature in mice (Rhodes et al., 2000).
The measured difference in the body temperature is substantial.
Genetic ablation of BAT in mice leads to an average reduction in body
temperature of about 1◦C (Klaus et al., 1998).
Future studies involving these mice are limited by the fact that due
to space limitations, this breeding has been reduced to a minimum in
house. Our collaborators in Zurich have expressed interest in pursu-
ing this study further in the future.
2.2.5.4 Material and Methods
measurements These results were generated with the help of
our collaborator Dr. Elvira Haas from the University Hospital of Zurich.
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3
A P P E N D I X
3.1 liver-specific knockout of rictor
During my PhD thesis, I established the technique of hepatocyte
isolations in our lab. I was involved in the characterization of the
liver-specific knockout of mTORC2 by isolating primary hepatocytes
and by generating and analyzing the immunofluorescent images. The
main characterization of these mice was performed by Asami Hagi-
wara. As many of the lysates used in my study come from liver-
specific Rictor knockout mice and their controls, this study is highly
relevant to my work and presented on the following pages.
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SUMMARY
Mammalian target of rapamycin complex 2
(mTORC2) phosphorylates and activates AGC kinase
family members, including Akt, SGK1, and PKC, in
response to insulin/IGF1. The liver is a key organ in
insulin-mediated regulation of metabolism. To
assess the role of hepatic mTORC2, we generated
liver-specific rictor knockout (LiRiKO) mice. Fed
LiRiKO mice displayed loss of Akt Ser473 phosphor-
ylation and reduced glucokinase and SREBP1c
activity in the liver, leading to constitutive gluconeo-
genesis, and impaired glycolysis and lipogenesis,
suggesting that the mTORC2-deficient liver is unable
to sense satiety. These liver-specific defects resulted
in systemic hyperglycemia, hyperinsulinemia, and
hypolipidemia. Expression of constitutively active
Akt2 in mTORC2-deficient hepatocytes restored
both glucose flux and lipogenesis, whereas glucoki-
nase overexpression rescued glucose flux but not
lipogenesis. Thus, mTORC2 regulates hepatic
glucose and lipid metabolism via insulin-induced
Akt signaling to control whole-body metabolic
homeostasis. These findings have implications for
emerging drug therapies that target mTORC2.
INTRODUCTION
Target of rapamycin (TOR) is a highly conserved protein kinase
that controls cell growth and metabolism in response to nutri-
ents, growth factors, and energy status. TOR exists in two
structurally and functionally distinct complexes termed TOR
complex 1 (TORC1) and TORC2 (Loewith et al., 2002). Mamma-
lian TORC1 (mTORC1) contains mTOR, raptor, and mLST8 and
phosphorylates a variety of substrates to control protein
synthesis, ribosome biogenesis, autophagy, and other growth-
related processes (Laplante and Sabatini, 2009; Polak and
Hall, 2009; Russell et al., 2011; Wullschleger et al., 2006). The
two best-characterized mTORC1 substrates are ribosomal
protein S6 kinase (S6K) and eukaryotic initiation factor 4E-
binding protein (4E-BP), both of which control protein synthesis.
mTORC2 comprises mTOR, rictor, mSin1, mLST8, and PRR5
(also known as protor) and phosphorylates members of the
AGC kinase family, including Akt (also known as PKB), SGK1,
and PKC, via which mTORC2 controls cell survival, actin cyto-
skeleton organization, and other processes (Cybulski and Hall,
2009; Garcı´a-Martı´nez and Alessi, 2008; Ikenoue et al., 2008;
Jacinto et al., 2006; Jacinto et al., 2004; Sarbassov et al.,
2004; Yang et al., 2006). By regulating a wide range of anabolic
and catabolic processes, themTOR complexes play a key role in
growth, development, metabolism, and aging and are implicated
in a variety of pathological states including cancer, obesity, and
diabetes (Dazert and Hall, 2011).
Many studieswith geneticallymodified animals indicatemTOR
signaling plays a role in whole-animal metabolism and in the
development of disease. Full-body knockout of any component
of mTORC1 or mTORC2 causes embryonic lethality (Gangloff
et al., 2004; Guertin et al., 2006; Jacinto et al., 2006; Murakami
et al., 2004; Shiota et al., 2006; Yang et al., 2006). More recent
studies have focused onmTOR function specifically in metabolic
tissues, in large part due to these tissues being particularly
sensitive to the three inputs that control mTOR (nutrients, insulin,
and energy status). Conditional knockout of raptor (mTORC1) in
skeletal muscle results inmuscle dystrophy, glucose intolerance,
and short lifespan, whereas knockout of rictor (mTORC2) in skel-
etal muscle confers little to no phenotype (Bentzinger et al., 2008;
Kumar et al., 2008). Adipose-specific raptor knockout mice
display increased energy expenditure and resistance to diet-
induced obesity (Polak et al., 2008). Adipose-specific rictor
knockout mice are characterized by increased glucose metabo-
lism and somatic growth due to high circulating levels of insulin
and IGF1 (Cybulski et al., 2009; Kumar et al., 2010). In podocytes,
mTORC1 plays a role in the development of diabetic nephrop-
athy, whereas mTORC2 appears to have a minor role (Go¨del
et al., 2011; Inoki et al., 2011). Recent findings suggest that
hepatic mTORC1 controls ketogenesis and possibly lipidmetab-
olism (Kenerson et al., 2011; Sengupta et al., 2010; Yecies et al.,
2011). Together, the above studies suggest that the two mTOR
complexes contribute to whole-body metabolic homeostasis
Cell Metabolism 15, 1–14, May 2, 2012 ª2012 Elsevier Inc. 1
Please cite this article in press as: Hagiwara et al., Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c,
Cell Metabolism (2012), doi:10.1016/j.cmet.2012.03.015
via distinct roles in different metabolic tissues. However, the role
of mTORC2 in the liver remains to be determined.
The liver plays a central role in whole-body glucose and lipid
homeostasis (Postic et al., 2004). In the fasted state, the liver
maintains blood glucose levels by producing glucose via
glycogen breakdown and via gluconeogenesis. In the postpran-
dial state (i.e., satiety—the increased availability of glucose and
insulin), the liver ceases to produce glucose and takes up ex-
cess circulating glucose to replenish glycogen and triglyceride
(TG) stores. Insulin is the major hormone controlling the fasted
to postprandial transition (Saltiel and Kahn, 2001). In type 2
diabetes, hepatic insulin resistance leads to altered glucose
metabolism and thereby hyperglycemia. Insulin signals through
the PI3K-Akt pathway to inhibit gluconeogenesis and activate
glycolysis and lipogenesis. Akt inhibits expression of gluconeo-
genic genes, by inhibiting FoxO (Puigserver et al., 2003), and
induces glycolytic and lipogenic genes, by activating sterol regu-
latory element-binding protein 1c (SREBP1c) and glucokinase
(GK). SREBP1c is a transcription factor that promotes expres-
sion of a number of lipogenic genes (Horton et al., 2002). GK,
the rate-limiting enzyme of glycolysis in the liver, stimulates
glycolysis and lipogenesis by enhancing glucose flux, including
production of acetyl-CoA for lipid synthesis (Foufelle and Ferre´,
2002). Furthermore, GK stimulates glycolysis and lipogenesis
at the transcriptional level via the carbohydrate responsive
element-binding protein (ChREBP) (Uyeda and Repa, 2006).
Thus, the combined action of insulin signaling and glucose flux
regulates glucose and lipid metabolism in the liver.
mTORC2 phosphorylates Ser473 in the so-called hydrophobic
motif of Akt and thereby activates Akt toward some but not all
substrates (Guertin et al., 2006; Jacinto et al., 2006; Sarbassov
et al., 2005; Shiota et al., 2006; Yang et al., 2006; Zinzalla
et al., 2011). To elucidate the role of mTORC2 in the liver in vivo,
we generated liver-specific rictor knockout mice and investi-
gated Akt signaling and glucose and lipid metabolism. We find
that the mTORC2-deficient liver is unable to sense the state of
satiety. Hepatic mTORC2 activates both Akt signaling and
glucose flux to control glucose and lipid metabolism in the liver
and thereby overall metabolic homeostasis.
RESULTS
mTORC2 Deficiency in the Liver Leads to
Hyperglycemia, Hyperinsulinemia, and Hypolipidemia
To investigate the role of mTORC2 in the liver, we generated
mice lacking rictor, an essential and specific component of
mTORC2, exclusively in the liver (see Experimental Procedures).
Liver-specific rictor knockout (rictorfl/fl Alb-CreTg/0) mice (LiRiKO
mice) were viable, born at the expected frequency for Mendelian
inheritance, and showed normal fertility. In all subsequent exper-
iments, littermates without the Cre transgene (rictorfl/fl) were
used as controls. In LiRiKO mice, rictor protein was absent
only in the liver (Figure S1A). To evaluate mTORC2 activity, we
investigated the phosphorylation status of mTORC2 substrates
in the liver of mice treated with insulin. mTORC2 phosphorylates
the hydrophobic (Ser473) and turn (Thr450) motifs in Akt (Facchi-
netti et al., 2008; Ikenoue et al., 2008; Jacinto et al., 2006; Sar-
bassov et al., 2005; Yang et al., 2006). Akt phosphorylation at
these two sites was significantly reduced in LiRiKO liver (Fig-
ure 1A). Phosphorylation of Akt Thr308, a site in the catalytic
loop phosphorylated by PDK1, was normal. mTORC2 also
phosphorylates and thereby controls the stability and activity
of PKCa and SGK1, respectively (Garcı´a-Martı´nez and Alessi,
2008; Ikenoue et al., 2008). As expected, PKCa protein levels
and phosphorylation of the SGK1 substrate NDRG1 were
decreased in LiRiKO liver (Figure 1A). These observations
confirm that both rictor protein and mTORC2 activity are absent
in the liver of LiRiKO mice.
We next examined systemic parameters of LiRiKO mice fed
a normal (chow) or high-fat diet (HFD). On a chow diet, LiRiKO
mice showed normal growth rates (Figure 1B) and normal body
composition (Figure S1B). When fed a HFD for 10 weeks, LiRiKO
mice were slightly lighter than controls, but this difference was
not statistically significant (Figure S1C). After 20 weeks on
a HFD, fat mass was significantly reduced (5%) in LiRiKO mice
(Figure S1D). This was likely due to increased lipolysis and
mitochondrial oxidation in adipose tissue of LiRiKO mice, as
suggested by an increased level of plasma glycerol (Figure S1E)
and increased expression of genes involved in lipolysis andmito-
chondrial oxidation in adipose tissue (Figure S1F). Analysis of
plasma parameters revealed that plasma TG and cholesterol
(total and HDL cholesterol) levels were significantly lower (Fig-
ure 1C), while plasma glucose (Figure 1D) and insulin (Figure 1E)
levels were significantly higher, in both fasted and chow-fed
LiRiKO mice. The same differences in blood parameters were
observed with mice on a HFD (Figures S1G–S1I). The levels of
ALT and AST were similar for the two genotypes (Figures S1J
and S1K). Thus, deletion of mTORC2 in the liver leads to hyper-
glycemia, hyperinsulinemia, and hypolipidemia, suggesting that
hepatic mTORC2 mediates metabolic homeostasis.
The liver of LiRiKO mice displayed normal gross morphology
(data not shown), and normal cell size and histopathology (Fig-
ure 1F). However, the weight of the liver of LiRiKO mice was
20% less compared to controls, for mice fed ad libitum either
a chow or a HFD (Figures 1G and S1L). This difference was not
observed in fasted mice (Figure S1M). Further analysis revealed
that glycogen and TG levels in the liver of fed LiRiKO mice were
significantly lower compared to controls (Figures 1F, 1H, 1I, and
S1N). Thus, loss of hepaticmTORC2 results in a smaller liver with
reduced glycogen and TG content in fed mice.
Deletion of mTORC2 in the Liver Causes Glucose
Intolerance
LiRiKO mice developed mild hyperglycemia and hyperinsuline-
mia at a young age (6 weeks), indicating that impaired glucose
homeostasis is an early effect of mTORC2 loss in the liver
(Figures S2A and S2B). To evaluate further whole-body glucose
homeostasis, we performed a glucose tolerance test (GTT) and
an insulin tolerance test (ITT). In the GTT, LiRiKO mice exhibited
significantly higher blood glucose levels before and after glucose
administration (Figure 2A). Plasma insulin levels were also signif-
icantly higher in LiRiKO mice (Figure 2B). The glucose intoler-
ance became more pronounced in older (>8 months) LiRiKO
mice (Figure S2C). In the ITT, when the mice were fasted for
6 hr before the experiment, LiRiKO mice showed normal insulin
sensitivity (Figure 2C). In contrast, when the mice were fasted
overnight, LiRiKO mice showed slightly but significantly
decreased glucose clearance (Figure 2D). The fact that lower
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Figure 1. LiRiKO Mice Develop Hyperglycemia, Hyperinsulinemia, and Hypolipidemia
(A) Western blots showing loss of rictor expression and mTORC2 activity in the liver of LiRiKO mice. Fasted mice were injected with insulin as described in
Experimental Procedures.
(B) Body weight (BW) gain of mice on a chow diet (n = 12 for control, n = 19 for LiRiKO). BW was monitored every week from 6 weeks of age for 26 weeks.
(C) Plasma total cholesterol (CHOL), HDL cholesterol (HDLC), LDL cholesterol (LDLC), and TG levels of ad libitum fed mice (n = 6 per group).
(D and E) Blood glucose (D) and plasma insulin (E) levels of overnight fasted and ad libitum fed mice (n = 8 for control and n = 6 for LiRiKO).
(F) Representative images of H&E, PAS, and oil red O staining of liver sections from ad libitum fed mice. Original magnification, 340.
(G) Liver weight (normalized to BW) of 10- to 18-week-old mice fed ad libitum (n = 12–13 per group).
(H) Hepatic glycogen content of mice after 4 hr refeeding (n = 7 per group).
(I) Hepatic TG content ofmice after 4 hr refeeding (n = 7 per group). Black bars represent control mice andwhite bars represent LiRiKOmice. Values are expressed
as mean ± SEM. * indicates statistical significance from control mice (*p < 0.05, **p < 0.01, ***p < 0.001).
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insulin sensitivity in LiRiKO mice was observed only after over-
night fasting, when hepatic gluconeogenesis is more active,
suggests that LiRiKO mice have hepatic insulin resistance but
normal insulin sensitivity in other tissues. Consistent with this,
insulin-induced activation of Akt was normal in both skeletal
muscle and adipose tissue in LiRiKO mice (Figure 2E). However,
older LiRiKO mice (>8 months) showed impaired glucose clear-
ance even after 6 hr fasting (Figure S2E), suggesting that whole-
body insulin sensitivity decreased with age as a consequence of
chronic hyperinsulinemia. When fed a HFD, LiRiKO mice dis-
played glucose intolerance (Figure S2F) and moderate insulin
resistance (Figure S2G) already at 14 weeks of age. Thus, LiRiKO
mice develop diabetes (glucose intolerance, hyperinsulinemia,
and insulin resistance), further suggesting that hepatic mTORC2
controls whole-body metabolic homeostasis.
HepaticmTORC2 Is Required for Insulin-Akt Signaling to
FoxO1 and GSK3a/b but Not to mTORC1
The above findings suggest that the primary defect of a hepatic
mTORC2 deficiency may be insulin resistance in the liver. To
investigate this further, we examined insulin signaling, in partic-
ular insulin-activated Akt signaling, in the liver. Previous studies
have shown that mTORC2 (i.e., Akt Ser473 phosphorylation)
appears to be necessary for Akt activity toward some but not
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Figure 2. Deletion of mTORC2 in the Liver Causes Glucose Intolerance
(A andB) Glucose tolerance test (GTT) in overnight fasted 14-week-oldmice.Micewere injectedwith glucose (2 g/kg) and blood glucose (A) and plasma insulin (B)
levels were measured at the indicated times. Bar graphs to the right show the respective area under the curve (AUC) of glucose and insulin (n = 7–8 per group).
(C and D) Insulin tolerance test (ITT) in 6 hr fasted (C) and overnight fasted (D) 16-week-old mice. Mice were injected with insulin (0.5 or 0.25 IU/kg, ip), and blood
glucose levels were measured at the indicated times. Results are expressed as percentage of the initial blood glucose levels. Bar graphs to the right show the
respective inverse area under the curve (AUC) of glucose (n = 6–7 per group).
Values are expressed as mean ± SEM. * indicates statistical significance from control mice (*p < 0.05, **p < 0.01, ***p < 0.001).
(E) Insulin-stimulated phosphorylation of Akt in the liver, skeletal muscle, and epididymalWAT of control and LiRiKOmice. Fourteen-week-oldmice were injected
with insulin as described in Experimental Procedures.
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all substrates (Guertin et al., 2006; Jacinto et al., 2006; Polak and
Hall, 2006; Sarbassov et al., 2005; Shiota et al., 2006; Yang et al.,
2006). We first analyzed the phosphorylation status of Akt and
several Akt downstream effectors in insulin-stimulated primary
hepatocytes. In control hepatocytes, insulin stimulated phos-
phorylation of Akt (Ser473 and Thr308), GSK3a/b (Ser21 and
Ser9), FoxO1 (Thr24), S6K (Thr389), and S6 (Ser235/236) (Fig-
ure 3A). In LiRiKO hepatocytes, insulin failed to stimulate Akt
Ser473 phosphorylation whereas Thr308 phosphorylation was
normal (Figure 3A), confirming our in vivo findings described
above. The Akt substrates GSK3a/b and FoxO1 were signifi-
cantly hypophosphorylated in insulin-treated LiRiKO hepato-
cytes (Figure 3A). Importantly, phosphorylation of the Akt down-
stream effectors S6K and S6 was normal, supporting the
previous finding that Ser473 phosphorylation is not necessary
for Akt to signal to mTORC1. Next, we examined Akt effectors
in the liver of fasted and refed mice. Refeeding stimulated phos-
phorylation in control and LiRiKO livers in the same manner as
observed in insulin-stimulated control and LiRiKO hepatocytes
(Figure 3B). The only noteworthy exception in results obtained
with hepatocytes versus livers is that Akt Thr308was hyperphos-
phorylated in the liver of fasted and refed LiRiKO mice (Fig-
ure 3B). This is consistent with the hyperinsulinemia and
increased tyrosine phosphorylation of the insulin receptor in
LiRiKO mice (Figure 3B). Thus, hepatic mTORC2 is required for
insulin-Akt signaling to FoxO1 and GSK3a/b, but not for
insulin-Akt signaling to mTORC1. Furthermore, these findings
confirm hepatic insulin resistance, albeit partial, in LiRiKO mice.
Loss of mTORC2 Results in Dysregulated Hepatic
Gluconeogenesis and Glycolysis
How might the observed defect in hepatic insulin signaling lead
to defects in metabolic homeostasis, e.g., hyperglycemia? As
shown above, FoxO1 is hypophosphorylated in the liver of
refed LiRiKO mice (Figure 3B). FoxO1 is a transcription factor
that functions with the transcriptional coactivator PGC1a to
induce gluconeogenic genes such as glucose-6-phosphatase
(G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) in
the fasted state. During the fasted to postprandial transition,
FoxO1 is phosphorylated by Akt, which results in nuclear exclu-
sion of FoxO1 and inihibition of gluconeogenesis (Matsumoto
et al., 2007; Puigserver et al., 2003). Consistent with hypophos-
phorylation of FoxO1 in the liver of LiRiKO mice, nuclear exclu-
sion of FoxO1 in response to feeding was severely impaired
(Figure 4A). Furthermore, visualization of FoxO1 by immunos-
taining revealed that FoxO1 is preferentially localized in the
nucleus in LiRiKO hepatocytes (Figures 4B and S3A). To further
investigate the regulation of gluconeogenesis, we examined
glucose production and gluconeogenic gene expression. LiRiKO
hepatocytes exhibited higher basal glucose production, which
was less inhibited by insulin, as compared to controls (Figure 4C).
Consistent with these observations, mRNA levels of PEPCK and
G6Pase in basal and insulin-treated conditions were significantly
higher in LiRiKO hepatocytes (Figure S3B). Higher mRNA levels
of gluconeogenesis-related geneswere also observed in the liver
of refed LiRiKO mice (Figure 4D). Finally, in a pyruvate challenge
test, LiRiKO mice showed mildly but significantly higher blood
glucose levels compared to controls, further suggesting
increased hepatic glucose production capacity (Figure S3C).
Thus, gluconeogenesis is constitutively active in the liver of LiR-
iKO mice, accounting for the observed high levels of blood
glucose in both fasted and fed LiRiKO mice.
To further investigate the cause of the hyperglycemia, we
examined hepatic glucose uptake and glycolysis. Glucose
uptake was significantly reduced in LiRiKO hepatocytes com-
pared to control hepatocytes (Figure 4E). Glucose uptake by
hepatocytes is determined by the rate of glycolysis which is
mainly dependent on GK activity (Ferre et al., 1996). GK, the
first enzyme in the glycolytic pathway, is induced by insulin
A
B
Figure 3. Hepatic mTORC2 Is Required for Insulin-Akt Signaling to
FoxO1 and GSK3a/b but Not to mTORC1
(A) Western blots of signaling molecules involved in the Akt and mTORC1
pathway in primary hepatocytes stimulated with 50 nM insulin for 30 min.
(B) Western blots of signaling molecules involved in the Akt and mTORC1
pathway in the liver of fasted and refed mice. Fourteen- to sixteen-week-old
mice (n = 4–6 per condition) were either fasted or refed a chow diet for 2 hr.
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Figure 4. Loss of mTORC2 Results in Active FoxO1 and Constitutively Elevated Hepatic Gluconeogenesis, Reduced Glucokinase Expres-
sion, and Glucose Flux
(A) FoxO1 protein levels in nuclear fractions from the liver of fasted and refed mice.
(B) Immunofluorescent staining of FoxO1 in primary hepatocytes isolated from control and LiRiKO mice.
(C) Glucose production from primary hepatocytes. Hepatocytes were incubated in glucose production media in the presence or absence of insulin, and glucose
release into the media was measured after 12 hr incubation. Results are representative of three independent experiments. Results are normalized to the level of
control without insulin.
(D) mRNA levels of G6Pase, PEPCK, and PGC-1a in the liver of control and LiRiKOmice after overnight fasting and after 4 hr of refeeding. Results are normalized
to the levels of fasted control mice.
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and converts glucose to glucose-6-phosphate (G6P). G6P is
metabolized through glycolysis, glycogen synthesis, and via
the pentose phosphate shunt. In the liver of LiRiKO mice, GK
was markedly decreased, as determined by the levels of GK
mRNA, protein, and activity (Figures 4F–4H). This correlated
with decreased ChREBP expression and nuclear translocation
(Figures 4F and S3D), and low expression of a ChREBP target
gene (L-pyruvate kinase) in LiRiKO liver (Figure 4F). Furthermore,
insulin-induced glycogen synthesis was also significantly
decreased in LiRiKO hepatocytes (Figure S3E). The reduced
glycogen synthesis in LiRiKO liver could be explained not
only by reduced glucose uptake, but also by lower glycogen
synthase (GS) activity, as indicated by higher GS phosphoryla-
tion (Figure S3F). This was consistent with the observed hypo-
phosphorylation of GSK3, a kinase responsible for inhibitory
phosphorylation of GS, in LiRiKO liver (Figure 3B). In contrast,
GLUT2 expression in the liver of LiRiKO mice was not changed
(Figures S3G and S3H). Taken together, these results indicate
that glucose uptake, glycolysis, and glycogen synthesis are
impaired in the liver of LiRiKO mice, possibly due to decreased
mTORC2-mediated insulin-induced GK expression. Thus,
constitutive gluconeogenesis and defective glycolysis (and
glycogen synthesis) together account for the observed hypergly-
cemia. Furthermore, the above findings suggest that defective
mTORC2-Akt signaling (hepatic insulin resistance) accounts for
the hyperglycemia in LiRiKO mice.
Hepatic mTORC2 Is Required for Insulin-Stimulated De
Novo Lipid Synthesis
The glycolytic defect described above and the decreased TG
levels in the liver of LiRiKO mice suggested that mTORC2 is
required for hepatic lipogenesis. Hepatic lipogenesis is induced
by insulin via stimulation of lipogenic gene expression. To
investigate lipogenesis, we examined both lipogenic gene
expression in the liver of refed mice and de novo lipid synthesis
in insulin-stimulated primary hepatocytes. mRNA levels of the
key lipid synthesis enzymes, including ATP citrate lyase
(ACL), acetyl-CoA carboxylase (ACC), fatty acid synthase
(FAS), stearoyl-CoA desaturase (SCD1), glycerol-3-phosphate
acyl transferase (GPAT), and diacylglycerol acyl transferase
(DGAT2), were all significantly decreased in the liver of refed
LiRiKO mice (Figure 5A). In addition, mRNA expression of
SREBP1c and PPARg, two transcription factors that activate
lipogenic genes, was significantly reduced in LiRiKO liver (Fig-
ure 5A). De novo lipid synthesis was also significantly decreased
in insulin-stimulated LiRiKO hepatocytes (Figure 5B). Thus,
impaired lipid synthesis in the liver of LiRiKOmice is due, at least
in part, to decreased expression of lipogenic genes. Conversely,
genes related to fatty acid oxidation, such as acyl-CoA oxidase
(ACO), carnitine palmitoyltransferase 1 (CPT1), and PPARa, were
increased in fasted LiRiKO mice (Figure S5A). This observation
together with a trend of increased plasma ketone bodies (b-hy-
droxybutyrate) (Figure S5B) suggests higher fatty acid oxidation
in the liver of LiRiKO mice. Moreover, expression of genes en-
coding fatty acid uptake, including fatty acid-binding protein 1
(FABP1) and CD36, was significantly decreased in the liver of
HFD-fed LiRiKO mice, while expression of genes encoding
fatty acid export, including ApoB and MTP, was unaffected (Fig-
ure S5C). Taken together, these observations suggest that the
mTORC2-deficient liver displays reduced TG levels due to
reduced lipogenesis, increased fatty acid oxidation, and
reduced uptake.
Postprandial expression of lipogenic genes ismediatedmainly
by insulin-induced activation of SREBP1c (Shimomura et al.,
1999). SREBP1c is synthesized as an ER bound precursor.
Upon activation by insulin, SREBP1c moves to the Golgi where
it is proteolytically processed into a mature form. The cleaved
mature form of SREBP1c translocates into the nucleus, where it
upregulates target lipogenic genes (Horton et al., 2002). Insulin-
mediated activation of SREBP1c is Akt dependent (Yellaturu
et al., 2009a). Interestingly, recent cell culture-based studies
suggest that Akt stimulates lipogenesis via mTORC1-dependent
SREBP1 activation (Du¨vel et al., 2010; Li et al., 2010; Peterson
et al., 2011; Porstmann et al., 2008; Yecies et al., 2011), whereas
mainly in vivo studies suggest that Akt activates SREBP1c and
lipogenesis via an mTORC1-independent pathway (Wan et al.,
2011; Yecies et al., 2011). To investigate further the role of
mTORC2(-Akt) signaling in lipogenesis, we examined SREBP1c
activation in the liver of refed LiRiKOmice. In particular, we exam-
ined the levels of precursor and mature forms of SREBP1c. The
mature nuclear form of SREBP1c was significantly decreased
in the liver of refed LiRiKO mice, whereas the precursor form
was unchanged (Figure 5C), suggesting that the posttranslational
activation of SREBP1c is defective in LiRiKO liver. Expression of
the SREBP1c target genes ACC and FAS was reduced (Figures
5A and 5C). Thus, mTORC2 is required for SREBP1c activation
and lipogenesis in the liver.
Constitutively Active Akt2 Restores Glucose Flux and
Lipogenesis in mTORC2-Deficient Hepatocytes
The above findings suggest that loss of hepatic mTORC2 results
in defective Akt activation (Ser473 phosphorylation) which even-
tually results in impaired metabolic homeostasis. To investigate
further whether loss of mTORC2-mediated Akt Ser473 phos-
phorylation is responsible for the defects in glycolysis and lipo-
genesis observed in LiRiKO hepatocytes, we determined if
a constitutively active Akt is able to suppress these defects. By
adenoviral gene transfer, we introduced an Akt2 mutant in which
Ser474 (equivalent to Ser473 in Akt1) is mutated to phosphomi-
metic aspartic acid (Akt2-S474D). This Akt mutant does not
require mTORC2 for activation and is thus considered con-
stitutively active. LacZ and wild-type Akt2 (Akt2-WT) were
used as controls. Insulin-stimulated phosphorylation of Akt
substrates FoxO1 and GSK3b was significantly reduced in
(E) 2-deoxyglucose uptake in primary hepatocytes. Results are representative of three independent experiments.
(F) mRNA expression levels of GK, liver-type pyruvate kinase (PK) and ChREBP in the liver of 4 hr refed mice. Results are normalized to the levels of control mice.
(G) Western blot analysis of GK expression in the liver of ad libitum fed mice.
(H) Enyzmatic activity of GK and hexokinase in the liver of ad libitum fed mice. Results are representative of three independent experiments. Black and dark gray
bars represent control, and white and light gray bars represent LiRiKO (n = 6–7 per group for mice). Values are expressed as mean ± SEM. * indicates statistical
significance from control, # indicates statistical significance from respective fasted or untreated control. (*, #p < 0.05, **, ##p < 0.01, ***, ###p < 0.001).
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lacZ- or Akt2-WT-expressing LiRiKO hepatocytes compared to
control hepatocytes (Figure 6A). In contrast, mild overexpression
of Akt2-S474D increased insulin-stimulated phosphorylation of
FoxO1 and GSK3b in LiRiKO hepatocytes, as in control hepato-
cytes (Figure 6A). Importantly, restoration of Akt signaling in
LiRiKO hepatocytes suppressed the previously observed
defects in glucose uptake (Figure 6B) and de novo lipid synthesis
(Figure 6C). Furthermore, Akt2-S474D restored expression of
GK, SREBP1c, and FAS, in LiRiKO hepatocytes (Figure 6D).
Thus, mTORC2-mediated Akt phosphorylation is essential for
insulin-induced glycolysis and lipid synthesis in the liver.
Restoration of Glucose Flux Is Not Sufficient to Rescue
De Novo Lipid Synthesis in mTORC2-Deficient
Hepatocytes
mTORC2-mediated Akt phosphorylation enhances both insulin
signaling and glucose flux, which then contribute to activation
of lipogenesis (see Introduction and above). To investigate if
the defect in lipogensis observed in LiRiKO hepatocytes is due
to a defect in glucose flux, we restored glucose flux by overex-
A
B
C
Figure 5. Hepatic mTORC2 Is Required for Insulin-
Stimulated De Novo Lipid Synthesis
(A) mRNA levels of genes involved in de novo lipid
synthesis including ACL, ACC1, FAS, SCD1, GPAT,
DGAT1/2, SREBP1c, and PPARg, in the liver of mice after
4 hr refeeding. Results are normalized to the levels of
control mice. Black bars represent control mice and white
bars represent LiRiKO mice (n = 6–7 per group).
(B) De novo lipid synthesis in primary hepatocytes. Serum-
starved primary hepatocytes were stimulated with 50 nM
insulin for 12 hr. 14C-labeled acetate incorporation into
cellular lipids was determined as described in Experi-
mental Procedures. Results are representative of three
independent experiments. Black and dark gray bars
represent control hepatocytes, and white and light gray
bars represent LiRiKO hepatocytes.
(C) SREBP1c processing was analyzed by western blot
analysis on nuclear and cytosolic fractions from the liver of
mice after 4 hr refeeding. The precursor form of SREBP1c
(SREBP1c(p)) was detected in cytosolic fraction andwhole
cell lysates, and the mature form of SREBP1c
(SREBP1c(m)) was detected in nuclear fraction. HDAC1
and Erk were used as marker proteins of nuclear and
cytosolic fractions, respectively. Protein levels of
SREBP1c target genes (ACC and FAS) were also analyzed
using whole-cell lysates. Bar graph to the right represents
quantification of band intensities of SREBP1c normalized
to its respective internal control. Average value from fasted
controls was set to 1. Values are the mean ± SEM, * indi-
cates statistical significance from control, and # indicates
statistical significance from respective insulin-untreated
control (*, #p < 0.05, **, ##p < 0.01, ***, ###p < 0.001).
pressing GK (Figure 7A) and examined if this
was sufficient to suppress the lipogenesis
defect. Overexpressed GK enhanced glucose
uptake to a similar extent in LiRiKO and control
hepatocytes (Figure 7B). Consistent with
elevated glucose uptake, expression of genes
encoding ChREBP, pyruvate kinase, and lipo-
genic enzymes (FAS, ACC1/2) was significantly
increased in GK-overexpressing LiRiKO and control hepato-
cytes (Figure 7C). However, the defect in de novo lipid synthesis
was not suppressed in LiRiKO hepatocytes (Figure 7D). Whereas
de novo lipid synthesis was significantly elevated upon GK over-
expression, the increase was similar to that observed in control
cells (about 2.6-fold), and LiRiKO hepatocytes still displayed
only 30% activity compared to control cells (Figure 7D). Thus,
glucose flux, although required, is not sufficient to induce lipo-
genesis. Overexpressed GK did not suppress the defect in Akt
Ser473 phosphorylation (Figure 7A) or rescue expression of
SREBP1c and its target gene SCD1 (Figure 7C), indicating that
activation of Akt and SREBP1c is essential for lipogenesis in
the liver. Taken together, the above findings suggest that
mTORC2 activates Akt, which stimulates glycolysis and lipogen-
esis via GK and SREBP1c (Figure 7E).
DISCUSSION
In this study, we demonstrate that deletion of mTORC2 in the
liver (LiRiKO mice) leads to enhanced gluconeogenesis and
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decreased glycolysis, glycogen synthesis, and lipogenesis in the
fed state, despite hyperglycemia and hyperinsulinemia. This
suggests that the mTORC2-deficient liver is unable to make
the fasted to postprandial transition. In other words, the
mTORC2-deficient liver cannot sense satiety. The constitutively
active gluconeogenesis was due to loss of both Akt Ser473
phosphorylation and FoxO1 inhibition, and decreased glycolysis
was due to reduced GK and glucose uptake. These two defects
in hepatic glucose metabolism in turn led to systemic hypergly-
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Figure 6. Expression of Constitutively
Active Akt2 Restores Glucose Uptake and
Lipogenesis in mTORC2-Deficient Hepato-
cytes
(A) Western blots of control (C) and LiRiKO (K)
hepatocytes infected with adenoviruses express-
ing lacZ, Akt2-WT, and Akt2-S474D. Infected cells
were serum starved and stimulated with 50 nM
insulin for 30 min.
(B) Glucose uptake by hepatocytes infected with
adenoviruses as in (A).
(C) De novo lipid synthesis in hepatocytes infected
with adenoviruses as in (A).
(D) mRNA expression levels of GK, SREBP1c, and
FAS in hepatocytes infected with adenoviruses as
in (A). Results are normalized to the levels of lacZ
expressing control hepatocytes.
Values are the mean ± SEM. * indicates statistical
significance from control in the same condition
and # indicates statistical significance from
respective lacZ expressing control (*, #p < 0.05, **,
##p < 0.01, ***, ###p < 0.001).
cemia and hyperinsulinemia. The
decreased hepatic lipogenesis was due
to reduced SREBP1c activation and low
glucose flux. Finally, constitutively active
Akt restored both glucose uptake and
lipogenesis, whereas overexpression of
GK (enhanced glucose flux) failed to
restore lipogenesis. Our findings sug-
gest that hepatic mTORC2 controls Akt
Ser473 phosphorylation, and thereby
GK and SREBP1c, to coordinate glucose
and lipid metabolism (Figures 7E and S5).
Another important observation in this
study is that LiRiKO mice are phenotypi-
cally similar (glucose intolerance, hy-
perglycemia, hyperinsulinemia, hypolipi-
demia, and smaller liver size with
decreased glycogen content) to many
other genetically modified mice that
have more severe defects in the hepatic
insulin-PI3K-Akt signaling pathway. The
mice with more severely defective insulin
signaling include liver-specific insulin
receptor knockout mice (Biddinger et al.,
2008; Michael et al., 2000), single and
double hepatic IRS1/2 knockout mice
(Dong et al., 2006; Kubota et al., 2008),
and mice with deletion of regulatory
subunits of PI3K in the liver (Miyake et al., 2002; Taniguchi
et al., 2006). Since insulin signaling is completely ablated in these
mice, a broad spectrum of downstream targets is affected,
including both mTORC1 and mTORC2. In contrast, deletion of
mTORC2 results in loss of phosphorylation of the hydrophobic
motif, including Akt Ser473 phosphorylation, in a subset of
AGC kinase family members, without affecting mTORC1
signaling. The loss of Akt Ser473 phosphorylation accounts for
constitutively active FoxO1 and GSK3 and for the loss of
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SREBP1c and GK activities, and thereby appears to be largely
responsible for the phenotype of LiRiKOmice. Thus, our findings
reveal a particularly important role for mTORC2 and Akt Ser473
phosphorylation in the hepatic insulin pathway in controlling liver
and whole-body metabolism.
Akt is a major regulator of insulin-induced lipogenesis in the
liver. Hepatic overexpression of constitutively active Akt or dele-
tion of hepatic PTEN increases TG synthesis (Horie et al., 2004;
Ono et al., 2003; Stiles et al., 2004). Conversely, liver-specific
deletion of Akt2, the major Akt isoform in the liver, protects
against diet- or PTEN loss-induced hepatic steatosis (He et al.,
0.0
1.0
2.0
3.0
4.0
LacZ Control
LacZ LiRiKO
GK Control
GK LiRiKO
A
C mRNA
GK short exp.
rictor
Akt-pS473
Akt
actin
Ctrl   KO   Ctrl   KO
GK
SREBP1c FAS ACC1L-PK
AU
ACC2 SCD1ChREBP
*
0
5
10
15
20
LacZ Control
LacZ LiRiKO
GK Control
GK LiRiKO
B
*
Glucose uptake
cp
m
/
g 
pr
ot
ei
n ###
###
D
0
50
100
150
200
250
LacZ Control
LacZ LiRiKO
GK Control
GK LiRiKO
de novo lipid synthesis
cp
m
/
g
pr
o
te
in
***
#
***
###
*
*
###
***
*
###
###
###
###
* ***
###
### ###
###
###
###
***
***
#
##
GK long exp.
LacZ
mTORC2
SREBP1c
Akt (Ser473)
glycolysis
lipogenesis
insulinglucose
glucokinase
E
Figure 7. Restoration of Glucose Flux Is Not
Sufficient to Rescue De Novo Lipid Syn-
thesis in mTORC2-Deficient Hepatocytes
(A) Western blots of hepatocytes infected with
adenoviruses expressing lacZ or GK.
(B) Glucose uptake by hepatocytes infected with
indicated adenoviruses.
(C) mRNA expression levels of glycolytic and
lipogenic genes. Results are normalized to the
levels of lacZ-expressing control hepatocytes.
(D) De novo lipid synthesis in hepatocytes infected
with indicated adenoviruses. Black and dark gray
bars represent control hepatocytes, white and
light gray bars represent LiRiKO hepatocytes.
Values are expressed as mean ± SEM of three
independent experiments. * indicates statistical
significance from control in the same condition
and # indicates statistical significance from
respective lacZ-expressing control (*, #p < 0.05, **,
##p < 0.01, ***, ###p < 0.001).
(E) Model for the role of mTORC2 in the liver.
2010; Leavens et al., 2009). Akt promotes
lipid synthesis primarily through the acti-
vation of SREBP1c, a master transcrip-
tion factor of lipogenic genes. How does
Akt activate SREBP1c? Several cell
culture-based studies have suggested
that Akt activates SREBP1c and lipogen-
esis via mTORC1 (Du¨vel et al., 2010; Li
et al., 2010; Porstmann et al., 2008; Ye-
cies et al., 2011). Furthermore, a recent
study showed that mTORC1 regulates
SREBP by controlling nuclear transloca-
tion of lipin1, an inhibitor of SREBP
activity (Peterson et al., 2011). However,
recent animal-based studies using liver-
specific TSC1 or Akt2 knockout mice
have shown that mTORC1 activation is
not sufficient to stimulate SREBP1c
without Akt signaling (Kenerson et al.,
2011; Wan et al., 2011; Yecies et al.,
2011). Yecies et al. presented evidence
that Akt activates SREBP1c via inhibition
of expression of Insig2, an anchor protein
that retains SREBP1c on the ER mem-
brane (Yellaturu et al., 2009b). Another
potential mechanism by which Akt acti-
vates SREBP1c is via Akt-mediated phosphorylation and inhibi-
tion of GSK3. GSK3 phosphorylates mature SREBP1 and
thereby promotes its degradation by the ubiquitin-proteasome
pathway (Bengoechea-Alonso and Ericsson, 2009; Kim et al.,
2004; Sundqvist et al., 2005). Which of the above mechanism(s)
of Akt-mediated activation of SREBP1c is defective in LiRiKO
mice? Our finding that SREBP1c activation and lipogenenesis
are impaired in LiRiKO liver, where mTORC2 is defective but
mTORC1 is active, suggest that Akt signals to SREBP1c in the
liver at least in part independently of mTORC1. Also, we
observed no significant difference in Insig2a expression in the
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liver of refed LiRiKO mice compared to controls (data not
shown). However, we did observe a defect in Akt-mediated
GSK3 phosphorylation and decreased expression of mature
SREBP1c. Thus, constitutively active GSK3 and enhanced
degradation of mature SREBP1c may be the mechanism under-
lying the observed defect in SREBP1c activation in LiRiKO mice.
Though Akt-activated SREBP1c is considered a primarymedi-
ator of insulin-stimulated lipogenesis, GK-activated glucose flux
also mediates induction of lipogenesis in the liver (Dentin et al.,
2005). In liver-specific GK knockout mice, glycolytic and lipo-
genic genes are not maximally induced upon refeeding, even
though SREBP1c activation is normal (Dentin et al., 2004). More-
over, a high carbohydrate diet induces expression of glycolytic
and lipogenic genes even in SREBP1c-deficient mice (Liang
et al., 2002). GK-dependent and SREBP1c-independent induc-
tion of glycolytic (pyruvate kinase) and lipogenic (FAS, ACC)
genes appears to be mediated by the transcription factor
ChREBP (Uyeda and Repa, 2006). GK is necessary for both
expression and activation of ChREBP. Therefore, GK/glucose
flux and SREBP1c act synergistically in the stimulation of lipo-
genesis. In the liver of LiRiKO mice, lipogenesis was impaired
due to a decrease in both GK and SREBP1c activity. The
decrease in GK expression in the liver of LiRiKO mice is due to
a decrease in Akt signaling (the defect is suppressed by acti-
vated Akt). GK gene expression is regulated by a number of
Akt-dependent transcriptional factors, including FoxO1, HIF-
1a/HNF4/p300, SREBP1c, LXRa, and PPARg (Hirota et al.,
2008; Kim et al., 2009;Massa et al., 2011; Roth et al., 2004).
Indeed, phosphorylation of FoxO1 and expression of SREBP1c
and PPARg were decreased in the liver of LiRiKO mice. Further
studies are required to determine which mTORC2-regulated
transcription factor(s) is lacking and thus unable to activate GK
expression in LiRiKO mice.
We provide evidence that overexpression of GK in LiRiKO
hepatocytes restores expression of glycolytic and lipogenic
genes in the absence of Akt Ser473 phosphorylation and
SREBP1cactivation.However, the level of de novo lipid synthesis
induced by GK overexpression in LiRiKO hepatocytes was less
than that of control hepatocytes overexpressing GK, despite
a similar rate of glucose uptake, suggesting that glucose flux is
not sufficient to stimulate lipogenesis. Akt signaling and
SREBP1cactivationarealso required for inductionof lipogenesis.
Thus, mTORC2 is required for the coordinated regulation, by GK
and SREBP1c, of insulin-induced glycolysis and lipogenesis.
In summary, the present study demonstrates the functional
importance of hepatic mTORC2 in the regulation of glucose
and lipid homeostasis. Hepatic mTORC2 inhibition results in
decreased glucose metabolism caused by decreased Akt
activity (loss of Akt Ser473 phosphorylation) and subsequently
reduced SREBP1c and GK activities. These defects in turn
lead to hyperglycemia and hyperinsulinemia. These findings
should be taken into account when considering clinical use of
emerging mTOR inhibitors that target mTORC2 in addition to
mTORC1 (Benjamin et al., 2011). Although detailed safety pro-
files of mTOR kinase inhibitors remain to be seen, inhibition of
mTORC2may contribute to adversemetabolic effects (Markman
et al., 2010; Zhang et al., 2011). Our findings suggest that a defect
in hepatic mTORC2 signaling could contribute to metabolic
disorders.
EXPERIMENTAL PROCEDURES
A complete version of Experimental Procedures is shown in Supplemental
Information.
Animals
rictorfl/fl mice were generated as described previously (Cybulski et al., 2009).
Liver-specific rictor knockout mice were generated by crossing rictorfl/fl mice
with transgenic mice expressing Cre recombinase under the control of the
hepatocyte specific albumin promoter (C57BL/6-Tg(Alb-cre)21Mgn/J; Jack-
son Laboratory). The resultant rictorfl/+ Alb-CreTg/0 progeny were crossed
with rictorfl/fl mice to obtain tissue-specific knockout mice (rictorfl/fl
Alb-CreTg/0), termed liver-specific rictor knockout (LiRiKO) mice. Littermates
without the Cre gene were used as wild-type control mice (rictorfl/fl). All exper-
iments were conducted on male mice between 12 to 17 weeks of age, unless
otherwise indicated. All experiments were performed in accordance with
federal guidelines and were approved by the Kantonales Veterinaeramt of
Kanton Basel-Stadt.
Glucose, Insulin, and Pyruvate Tolerance Tests
For glucose tolerance tests (GTT), mice were fasted overnight (16 hr) then
administrated 2 g/kg of body weight of glucose by intraperitoneal (i.p.) injec-
tion. For insulin tolerance tests (ITT), mice were fasted for 6 hr or overnight
before i.p. administration of 0.5 or 0.25 unit/kg of body weight of insulin
(Actrapid). For pyruvate challenge test, mice were fasted overnight then
administrated 2 g/kg of body weight of sodium pyruvate by i.p. injection. Blood
glucose concentrations were measured before and after the injection at the
indicated time points.
Adenovirus Generation
We generated adenoviruses encoding wild-type Akt2 and a phosphomimetic
Akt2-S474D mutant using the ViraPower Adenoviral Gateway Expression
System (Invitrogen). In brief, wild-type human Akt2 and a phosphomimetic
Akt2-S474D mutant, in which Ser at residue 474 is substituted by Asp, were
subcloned by PCR from pFastBac-PKBb and pFastBac- PKBb-S474D clones
(clones were kind gifts of Brian A. Hemmings, FMI, Switzerland) and cloned
into pDONR221 vectors. Entry clones and the pAd/CMV-DEST vector
were recombined to generate expression clones (pAd/CMV-Akt2-WT and
pAd/CMV-Akt-S474D). Each expression clone was transfected into
HEK293A cells to produce adenoviruses. After several amplifications by infect-
ing HEK293A cells, we determined the titer of each adenovirus. AxCA-GK and
AxCA-lacZ adenoviruses were a kind gift of Wataru Ogawa (Kobe University,
Japan).
Primary Hepatocyte Isolation and Cultures
Hepatocytes were isolated from 8- to 12-week-old male mice using the stan-
dard two-step collagenase perfusion protocol. Adenoviral infection experi-
ments were performed 3 hr after plating at an moi of 1 for Akt2 restoration
and moi of 5 for GK restoration. Six hours after infection, cells were washed
with PBS and incubated overnight with DMEM (5 mM glucose) containing
100 nM dexamethasone and 1 nM insulin. Experiments were performed the
next day. For insulin stimulation, hepatocytes were cultured in high glucose
DMEM (25 mM glucose) with 10 or 50 nM insulin for the indicated times.
Western Blotting
Whole-protein extraction from tissuewas performed as described (Polak et al.,
2008). Nuclear and cytosolic fractions were prepared using the NE-PER
nuclear protein extraction kit (Pierce). Lysates from primary hepatocytes
were prepared using lysis buffer containing 50 mM Tris-HCl (pH 8.0),
150 mM NaCl, 0.5 mM EDTA, 1% Triton, protease inhibitor, and phosphatase
inhibitor. Forty micrograms of protein were loaded for SDS-PAGE and
analyzed with the indicated antibodies. Immunoblots were performed using
the antibodies against the following proteins: rictor, Akt, Akt (pThr308), Akt
(pSer473), GSK3a/b, GSK3a/b (pSer9/21), FoxO1, FoxO1/3a (pThr24/32),
IRb/IGFRb, IRb/IGFRb (pTyr1146/1131), S6K1, S6K1 (pThr389), S6, S6
(pSer235/236), 4EBP, 4EBP (pThr37/46), ACC, FAS, Erk, and HDAC (all from
Cell Signaling), glucokinase and SREBP1c (Santa Cruz), ChREBP (Novus
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Biologicals), Glut2 (a kind gift from Bernard Thorens, University of Lausanne,
Switzerland), and actin (Chemicon).
RNA Isolation and Quantitative PCR
RNA isolation and cDNA synthesis were performed as described (Polak et al.,
2008). qPCR was performed using the power SYBR green mix (Applied
Biosystems) and quantitated using Applied Biosystems StepOnePlus Real-
Time PCR Systems (Applied Biosystems). Duplicate runs of each sample
were normalized to 16S rRNA (liver) or cyclophilin (hepatocytes) to determine
relative expression levels. The sequences for the primer pairs used in this
study are listed in Table S1.
Glucose Production Assay
Glucose production assay was performed following Yoon et al. (2001) with
modifications. Briefly, primary hepatocytes were cultured in DMEM (5 mM
glucose) containing 100 nM dexamethasone in the presence or absence of
50 nM insulin for 16 hr. Cells were washed three times with glucose-free
DMEM without phenol red and then incubated with glucose production solu-
tion containing 2 mM sodium pyruvate, 20 mM lactate, 100 nM dexametha-
sone, and 1 mM 8-bromo-cAMP with or without 100 nM insulin. After 12 hr
of incubation, glucose concentration in the media was measured using
a glucose oxidase kit (Sigma), normalized to the protein amount of the cells.
The assay was done in triplicate and values were expressed as arbitrary units
relative to control hepatocytes without insulin.
Measurement of Glucose Uptake
Glucose uptake by primary hepatocytes was analyzed following Yang et al.
(2002) with modifications. Briefly, after 12 hr serum starvation, cells were
cultured in DMEM containing 25 mM glucose, 100 nM dexamethasone, and
10 nM (in the Akt2 restoration experiment) or 50 nM (in the GK restoration
experiment) insulin for 12 hr. To measure the rate of glucose uptake, cells
were washed three times with PBS and then incubated for 3 hr in DMEM con-
taining 1 mCi/ml 2-Deoxy-2[1,2-3H]glucose (PerkinElmer Life Sciences). The
cells were washed three times with ice-cold PBS and solubilized in 1% SDS.
The radioactivity of an aliquot was determined in a scintillation counter. Each
assay was done in triplicate, and results were expressed as cpm in the cell
lysate/mg of protein.
De Novo Lipid Synthesis Measurement
For de novo lipogenesis analysis, primary hepatocytes were precultured in the
same way as for the glucose uptake experiment. Then cells were incubated in
culture medium containing 0.5 mM sodium acetate and 0.8 mCi/ml [1-14C] ace-
tic acid (Amersham) for 2 hr. After washing with PBS, the cells were lyzed in
0.5 M KOH. The lysates were neutralized with 6% Na2SO4, then the lipids
were extracted using sequential extraction with chloroform:methanol (2:1)
and chloroform:methanol:H2O (10:10:3). Radioactivity in lipid-containing
phase was measured using scintillation counter. Each assay was done in trip-
licate, and results were expressed as cpm in the original cell lysate/mg of
protein.
Statistical analysis
Student’s unpaired t test was used to determine differences among two
groups. Significance was judged when p value is less than 0.05. Error bars
in figures represent standard error of the mean (SEM).
SUPPLEMENTAL INFORMATION
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Ass ee vlaicht vun iech Hären,
Dien d’ Saach méi klor gesait?
Ech wëll nun alles wëssen,
An och wou d’ Wourecht lait.
Et ginn duerch d’ Welt zwéi Weën:
Sief Wollef oder Schof!
E gudde Fuuss ass béides
Als echte Philosoph.
— Michel Rodange
Renert oder de Fuuss am Frack an a Ma’nsgrësst (1872)
colophon
This document was typeset using the typographical look-and-feel
classicthesis developed by André Miede. The style was inspired
by Robert Bringhurst’s seminal book on typography “The Elements of
Typographic Style”. classicthesis is available for both LATEX and LYX:
http://code.google.com/p/classicthesis/
Final Version as of October 3, 2012 (classicthesis version 4.0).
